var title_f10_49_11024="Skin vasculitis in lupus";
var content_f10_49_11024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpuric lesions on the shins in a patient with lupus and necrotizing vasculitis of the skin, kidney, and brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11024=[""].join("\n");
var outline_f10_49_11024=null;
var title_f10_49_11025="Algorithm eval rx CPP adol";
var content_f10_49_11025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Protocol for evaluation and treatment of adolescent pelvic pain/endometriosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 658px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAIDS: Nonsteroidal anti-inflammatory drugs; CHT: combination hormonal therapy (oral contraceptive pills, estrogen/progestin patch, estrogen/progestin vaginal ring); Progestins: norethindrone acetate, medroxyprogesterone acetate; GnRH: gonadotropin-releasing hormone agonist; add-back: estrogen + progestin or norethindrone acetate alone.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Laufer, MR, Sanfilippo, J, Rose, G. Adolescent endometriosis: diagnosis and treatment approaches. J Pediatr Adolesc Gynecol 2003; 16(3 Suppl):S3-11. Copyright &copy;2003 North American Society for Pediatric and Adolescent Gynecology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11025=[""].join("\n");
var outline_f10_49_11025=null;
var title_f10_49_11026="Substernal goiter CT I";
var content_f10_49_11026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Appearance on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing large obstructive goiter at level of clavicular heads with concentric narrowing of the tracheal lumen and displacement of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11026=[""].join("\n");
var outline_f10_49_11026=null;
var title_f10_49_11027="Coccidioidomycosis chest CT";
var content_f10_49_11027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest computed tomograph of a patient with coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution computed tomography (CT) image (1.5-mm collimation) shows thin-walled cavity in right upper lobe. The diagnosis of coccidioidomycosis was made at surgical resection. The patient was a 44-year-old man who developed coccidioidomycosis following travel to an endemic area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fungal and parasitic infections. In: Imaging of pulmonary infections. Muller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11027=[""].join("\n");
var outline_f10_49_11027=null;
var title_f10_49_11028="C1 inhibitor concentrate (human): Pediatric drug information";
var content_f10_49_11028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   C1 inhibitor concentrate (human): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"    see \"C1 inhibitor concentrate (human): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/54/38755?source=see_link\">",
"    see \"C1 inhibitor concentrate (human): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6759053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;;",
"     </li>",
"     <li>",
"      Cinryze&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13261898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F7715627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F7715637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"      see \"C1 inhibitor concentrate (human): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment, abdominal or facial hereditary angioedema attacks (Berinert&reg;): Adolescents and Adults: I.V.: 20 units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prophylaxis, hereditary angioedema attacks (Cinryze&reg;): Adolescents and Adults: I.V.: 1000 units every 3-4 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6764799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Berinert&reg;: 500 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cinryze&reg;: 500 units [contains sucrose 21 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6764774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11368727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assistance with procurement and reimbursement of Cinryze&reg; is available for healthcare providers and patients through the CINRYZE",
"     <i>",
"      Solutions",
"     </i>",
"     &reg; program (telephone: 1-877-945-1000) or at file://www.cinryze.com/Cinryze_Solutions/Default.aspx",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7715638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Berinert&reg;: Allow vials to come to room temperature. Reconstitute each vial with 10 mL of SWI using the provided transfer set; final concentration: 50 units/mL. After combining with diluent, gently swirl vial to completely dissolve powder. Do not use if turbid, discolored, or contains particles. Administer I.V. at recommended infusion rate: 4 mL/minute (200 units/minute); pH: 4.5-8.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinryze&reg;: Allow vials to  come to room temperature. Do not use product if there is no vacuum in the vial. Reconstitute each vial with 5 mL of SWI using the provided transfer set; final concentration 100 units/mL. After combining with diluent, gently swirl vial to completely dissolve powder. Reconstituted product should be clear and colorless or slightly blue; do not use if turbid, discolored, or contains particles. Administer I.V. at recommended infusion rate: 1 mL/minute (100 units/minute); pH:6.6-7.4",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7715634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F); do not freeze.",
"     <b>",
"      Protect from light",
"     </b>",
"     prior to reconstitution. Once reconstituted, product should be clear and colorless or slightly blue; do not use if turbid, discolored, or contains particles; use within 3 hours (Cinryze&reg;) or 8 hours (Berinert&reg;) of reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7715628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Berinert&reg;: Treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) (FDA approved in adolescents and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinryze&reg;: Routine prophylaxis against angioedema attacks in patients with HAE (FDA approved in adolescents and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6764808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain/discomfort, abnormal taste, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Vulvovaginal fungal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Infusion-related reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Nasopharyngitis,upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Flu-like syndrome, hereditary angioedema attack symptoms exacerbated, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Anaphylactic reaction, chills, hypersensitivity reaction, injection site erythema, injection site pain, shock, stroke, thrombotic events, transient ischemic attack",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7715630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or history of anaphylactic reactions to human C1 esterase inhibitor (C1-INH) preparations or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F11597029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential risk of thrombosis with use; thrombotic events have been reported when used at doses higher than recommended; monitor patients with risk factors for thrombotic events. Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors reduces the risk, as does testing and/or inactivation or removal of certain viruses. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7715631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions (eg, urticaria, hives, wheezing, hypotension, anaphylaxis) may occur rarely during or after administration. Signs and symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema; therefore, consideration should be given to treatment methods. In the event of acute hypersensitivity reactions to C1-INH therapy, treatment should be discontinued and epinephrine should be available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6764785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6764777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6764778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Information related to use during pregnancy is limited. Pregnancy may increase the incidence of attacks in patients with HAE.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11598643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patient closely for hypersensitivity reaction during or after administration (epinephrine should be immediately available). Teach patient possible side effects/appropriate interventions and adverse symptoms to report.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7715635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C1-INH, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1-INH therapy in patients with C1-INH deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F11598284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     C1-INH plasma concentration increase: Cinryze&reg;: 1 hour or less",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Symptom relief: Berinert&reg;: Median: 20 minutes per attack",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7715636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : Berinert&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: (6-13 years, n=5): 0.02 L/kg (range: 0.017-0.026 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 0.018 L/kg (range: 0.011-0.028 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Berinert&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 22 hours (range: 20-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 22 hours (range: 17-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cinryze&reg;: 56 hours (range: 11-108 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Cinryze&reg;: ~4 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7715639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/54/38755?source=see_link\">",
"      see \"C1 inhibitor concentrate (human): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new prescriptions, OTC medications, or herbal products during therapy without consulting prescriber. This medication can only be administered by infusion. Report immediately any pain, burning, or swelling at infusion site or any signs of allergic reaction (eg, respiratory difficulty or swallowing, back pain, chest tightness, rash, hives, swelling of lips or mouth). You may experience headache, abdominal pain, abnormal taste, or symptoms of respiratory infection. Report if rash occurs or other adverse reactions persist.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F7715640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Any infection suspected to have been transmitted from the administration of C1 inhibitor should be reported to the manufacturer (Berinert&reg;: CSL Behring, 1-866-915-6958; Cinryze&reg;: ViroPharma Biologics, Inc., 1-877-945-1000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     1 unit of Cinryze&reg; corresponds to C1 inhibitor present in 1 mL of normal fresh plasma",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Wasserman RL, Levy RJ, Bewtra AK, et al, \"Prospective Study of C1 Esterase Inhibitor in the Treatment of Successive Acute Abdominal and Facial Hereditary Angioedema Attacks,\"",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2011, 106(1):62-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16458 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11028=[""].join("\n");
var outline_f10_49_11028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759053\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13261898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715627\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715637\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764799\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764774\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368727\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715638\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715634\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715628\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764808\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715630\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11597029\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715631\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298919\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764785\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764777\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11598643\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715635\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11598284\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715636\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715639\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7715640\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16458|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=related_link\">",
"      C1 inhibitor concentrate (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/54/38755?source=related_link\">",
"      C1 inhibitor concentrate (human): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11029="Entecavir: Patient drug information";
var content_f10_49_11029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Entecavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     see \"Entecavir: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baraclude&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4297830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Baraclude&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis may get worse if this drug is stopped. Close watching is needed when therapy is stopped. HIV testing may be offered. Any HIV infection may be hard to treat after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis B infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to entecavir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for both hepatitis B and AIDS, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Raised liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood or sugar in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 2 hours before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696106",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given (delay feeding for 2 hours after getting this drug).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect oral solution from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11346 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11029=[""].join("\n");
var outline_f10_49_11029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165232\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4297830\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027452\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027454\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027453\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027458\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027459\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027461\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027456\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027457\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027462\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027463\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=related_link\">",
"      Entecavir: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11030="Group prenatal care";
var content_f10_49_11030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group prenatal care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Sharon Schindler Rising, MSN, CNM, FACNM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11030/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/49/11030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10245776\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1989, a Public Health Service Expert Panel on the Content of Prenatal Care published a report entitled, &ldquo;Caring For Our Future: the Content of Prenatal Care,&rdquo; which identified the pregnant woman, the fetus and infant, and the family as the three areas upon which prenatal and postpartum care should focus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/1\">",
"     1",
"    </a>",
"    ]. Specific objectives were identified for each of these areas.",
"   </p>",
"   <p>",
"    The objectives for the pregnant women were to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase her well-being before, during, and after pregnancy and to improve her self-image and self-care",
"     </li>",
"     <li>",
"      Reduce maternal mortality and morbidity, fetal loss, and unnecessary pregnancy intervention",
"     </li>",
"     <li>",
"      Reduce the risks to her health prior to subsequent pregnancies and beyond childbearing years",
"     </li>",
"     <li>",
"      Promote the development of parenting skills",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The objectives for the fetus and infant were to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase well-being",
"     </li>",
"     <li>",
"      Reduce preterm birth, intrauterine growth restriction, congenital anomalies, and failure to thrive",
"     </li>",
"     <li>",
"      Promote healthy growth and development, immunization, and health supervision",
"     </li>",
"     <li>",
"      Reduce neurologic, developmental, and other morbidities",
"     </li>",
"     <li>",
"      Reduce child abuse and neglect, injuries, preventable acute and chronic illness, and the need for extended hospitalization after birth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The objectives for the family during pregnancy and the first year of the infant&rsquo;s life were to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Promote family development and positive parent-infant interaction",
"     </li>",
"     <li>",
"      Reduce unintended pregnancies",
"     </li>",
"     <li>",
"      Identify for treatment behavior disorders leading to child neglect and family violence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the traditional one-to-one approach to prenatal care has not accomplished all of these objectives, a group model for well-woman prenatal care was developed and implemented (sometimes termed CenteringPregnancy). Subsequently, a group model of",
"    <span class=\"nowrap\">",
"     well-woman/well-child",
"    </span>",
"    care was also developed (sometimes termed CenteringParenting). Centering is built on the premise that care is most effectively and efficiently provided in groups that are facilitated rather than taught.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2481780\">",
"    <span class=\"h1\">",
"     DESCRIPTION OF GROUP PRENATAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2482445\">",
"    <span class=\"h2\">",
"     Pilot program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The model for group prenatal care was first reported by a nurse-midwife in Connecticut [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial impetus for developing this model was the nurse-midwife&rsquo;s observation that patients often had similar questions, leading to repetitive answers to questions that might have been better addressed by peers or more efficiently in a group setting. In addition, she wanted to take advantage of the power for behavioral change that exists within a group.",
"   </p>",
"   <p>",
"    The program was piloted in a hospital clinic, a community health clinic, and in a private obstetrics and gynecology office. In each of these settings, after their initial prenatal visit, women were invited to join a group of 8 to 12 other women with a similar estimated date of delivery. The group met for 10 90-minute visits at regular intervals throughout pregnancy and the early postpartum period.",
"   </p>",
"   <p>",
"    Prenatal care was provided in an appropriate large space where patients received their health assessments and discussed topics of interest to them with their care provider, as well as interacted informally with other pregnant women, caregivers, and support people. These sessions were led by skilled group leaders, trained in facilitative leadership, who also coordinated the assessment component of care. This model has been adopted at over 300 sites, public and private, throughout the United States and internationally [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2482452\">",
"    <span class=\"h2\">",
"     CenteringPregnancy model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CenteringPregnancy&reg; care model contains three components: health assessment, education, and support or community-building, all &ldquo;centered&rdquo; within a single, group space. The model is defined by 13 essential elements that provide its structure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Health assessment occurs within the group space",
"     </li>",
"     <li>",
"      Women are involved in self-care activities",
"     </li>",
"     <li>",
"      A facilitative leadership style is used",
"     </li>",
"     <li>",
"      Each session has an overall plan",
"     </li>",
"     <li>",
"      Attention is given to the core content, but emphasis may vary",
"     </li>",
"     <li>",
"      There is stability of group leadership",
"     </li>",
"     <li>",
"      Group conduct honors the contribution of each member",
"     </li>",
"     <li>",
"      The group is conducted in a circle",
"     </li>",
"     <li>",
"      Group composition is stable, but not rigid",
"     </li>",
"     <li>",
"      Group size is optimal to promote the process",
"     </li>",
"     <li>",
"      Involvement of family support people is optional",
"     </li>",
"     <li>",
"      Opportunity for socializing within the group is provided",
"     </li>",
"     <li>",
"      There is ongoing evaluation of outcomes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 13 essential elements that define this model may be the basis for the success of this relationship-based approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418594\">",
"    <span class=\"h2\">",
"     Designing a system for group prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moving care into groups takes considerable planning by a steering committee, along with support and expertise from all the staff. A steering committee composed of an administrator, one to two providers, a consumer, and a representative of each of the service areas (such as front desk, nursing, social work, medical assistants) does a system assessment to identify the system components most in need of redesign. These include determining appropriate space, scheduling, marketing, patient recruitment strategy, community support, and initial and ongoing funding. This group may work with a consultant from the Centering Healthcare Institute to prepare the system and then schedule basic training for those who will be involved with the groups.",
"   </p>",
"   <p>",
"    Following training, ideally the first group should start within a month and the site should continue to start at least one group a month. The consultant continues to help the site overcome challenges, to set benchmarks and institute an evaluation plan, and to prepare for site approval. This site approval visit will assess the group model for implementation of the essential elements, as well as the success in addressing the standards for sustainability of the group model [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/7\">",
"     7",
"    </a>",
"    ]. Before introducing groups to their system, the site champion and steering committee members are encouraged to do a self-assessment of readiness that includes estimating the size of the patient population and assessing the availability of interested providers, appropriate group space, and administrative support.",
"   </p>",
"   <p>",
"    Although the site may start one group a month for two to three months as a pilot, we recommend that the facility promptly move forward with ongoing groups starting at least once a month and develop a plan to include at least 60 percent of eligible women in the group care system.",
"   </p>",
"   <p>",
"    After a standard initial prenatal visit and reaching 12 to 16 weeks of pregnancy, women meeting preselected criteria (eg, low risk or specific types of higher risk pregnancies) are invited to join a group. Groups need to have 8 to 12 women in them for the most effective group dynamics and to be financially viable. More than one",
"    <span class=\"nowrap\">",
"     provider/facilitator",
"    </span>",
"    team, which can be comprised of nurse midwives, nurse practitioners,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physicians, is needed to be sure there is adequate coverage, and administrative support is essential. At the first session, 10 two-hour group sessions are scheduled over a six-month period, allowing the participants to plan their work and child care needs. The group&rsquo;s sessions are never referred to as classes, a term that denotes the traditional, didactic model of",
"    <span class=\"nowrap\">",
"     teacher/student",
"    </span>",
"    interaction.",
"   </p>",
"   <p>",
"    Women entering the facility go directly to their group room, where there is formal check-in, health assessment with the provider, and structured circle time for group discussion led by a facilitator. The sessions start and end on time, and there is activity during the entire two-hour time period, with no idle time.",
"   </p>",
"   <p>",
"    Moving care out of examination rooms and into group space affects the delivery of health care and often requires redesign of the care delivery system before implementing the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/8\">",
"     8",
"    </a>",
"    ]. One of the biggest challenges is providing appropriate space. The area needs to be at least 25 by 25 feet with room for an open circle of at least 20 chairs. The space should be inviting, private, and with easy access. Ideally, it has windows for natural light and a rug on the floor.",
"   </p>",
"   <p>",
"    The check-in area should include appropriate equipment for health assessment and the patients&rsquo; charts so the women can perform and record their self-assessments (eg, weight, blood pressure, fundal height). This data collection may be done under the supervision of, or with the assistance of, a nurse or medical assistant. A clinician performs individual patient assessments in an area at the side of the room with a floor mat or low massage table that can be used for the brief check-up (chart review, fetal position, fetal heart rate, review of",
"    <span class=\"nowrap\">",
"     laboratory/imaging",
"    </span>",
"    results). Music provides added privacy so that provider-patient conversations are not overheard.",
"   </p>",
"   <p>",
"    Topics that are discussed during group circle time can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutrition",
"     </li>",
"     <li>",
"      Pregnancy discomforts",
"     </li>",
"     <li>",
"      Preparation for labor and delivery",
"     </li>",
"     <li>",
"      Mental health and depression",
"     </li>",
"     <li>",
"      Issues of abuse",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"     <li>",
"      Expectations for bringing your baby home from the hospital",
"     </li>",
"     <li>",
"      Post-pregnancy contraception&nbsp;",
"     </li>",
"     <li>",
"      Parenthood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28874127\">",
"    <span class=\"h1\">",
"     BENEFITS OF GROUP PRENATAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In traditional prenatal care, education and support often require extra visits that are relatively inefficient for both the provider and the patient. Providers repeatedly answer the same questions asked by different patients; answering the questions once for a group of women is more efficient and the group setting allows all participants to get the benefit of hearing answers to questions they may not have thought to ask.",
"   </p>",
"   <p>",
"    In traditional practices, patients spend too much time waiting, often in crowded waiting rooms and then again in examination rooms or offices, and the flow from check-in to actual encounter is inefficient for both the patient and the provider. By concentrating resources within the group space, the group model is efficient, since fewer examination rooms are needed for prenatal care, and personnel (eg, translators, nutritionists, genetic counselors, nurses) can serve multiple patients at one time. However, cost savings compared to traditional care depend on the specific setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Billing practices for group care vary among states and insurers.",
"   </p>",
"   <p>",
"    Groups can sometimes help individuals achieve goals that would be unattainable or more difficult to obtain by the individual alone. They provide a venue for women to meet other women, the support of a community, and an opportunity for shared learning and skill-development. They can be organized for women who speak the same non-native language, and thus improve communication for these women.",
"   </p>",
"   <p>",
"    Within groups, there is the potential to develop many relationships: provider (facilitator) to patient (group members), participants to one another, providers to each other and other professionals and staff people, providers to the community, participants to the community, and provider and participants to self. This relationship building is what helps to support the development of communities of empowerment and increase patient satisfaction. Group care can help women understand how to navigate a complicated, and often frightening, healthcare system and take an active role in determining how their needs can be met with the right type of care when it is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For some women, interacting with others on an emotional level appears to increase their motivation to change behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. This may lead to improvement in some pregnancy outcomes, such as a reduction in late preterm birth (see",
"    <a class=\"local\" href=\"#H28874143\">",
"     'Evidence'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Groups can also bring new energy to a provider&rsquo;s practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28874143\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies comparing outcomes of group versus individual prenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/17\">",
"     17",
"    </a>",
"    ]. A randomized trial and prospective and retrospective cohort studies have provided some evidence that group prenatal care is associated with improved pregnancy outcome (decrease in preterm birth) and greater patient satisfaction than standard individual prenatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/9,18-21\">",
"     9,18-21",
"    </a>",
"    ]. In contrast, enhanced prenatal care consisting of more visits or more information using didactic approaches has not been associated with a reduction in preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H29#H29\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Enhanced prenatal care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H1#H1\">",
"     \"Initial prenatal assessment and patient education\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A multicenter trial randomly assigned 1047 women aged 14 to 25 years to group or standard individual prenatal care [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/9\">",
"       9",
"      </a>",
"      ]. Women assigned to group care were significantly less likely to have preterm births &lt;37 weeks of gestation compared with those in standard care (9.8 versus 13.8 percent; OR 0.67, 95% CI 0.44-0.99), with the strongest effect in African-American women (10.0 versus 15.8 percent; OR 0.59, 95% CI 0.38-0.92) and among late preterm births (35 to 37 weeks). However, there was no significant difference in mean gestational age at birth or birth weight, or the frequency of low birth weight or small for gestational age infants.",
"      <br/>",
"      <br/>",
"      Initiation of breastfeeding was higher among women who were assigned to group prenatal care (OR 1.77, 95% CI 1.28-2.35) and fewer women in the group care model missed prenatal care appointments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A prospective matched cohort study including 458 women compared the impact of group versus standard individual prenatal care on the outcome of birth weight and gestational age at delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/18\">",
"       18",
"      </a>",
"      ]. Group prenatal care was associated with higher mean birth weights (3228 versus 3159 grams), especially for infants born preterm (2398 versus 1990 grams). Although not statistically significant, infants of patients in group care were less likely than those in individual care to be low birth weight (16 versus 23 infants), very low birth weight (3 versus 6 infants), less than 33 weeks gestational age (2 versus 7 infants), or to experience neonatal death (none versus 3 infants).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A retrospective cohort study including 316 low risk women receiving group prenatal care and 3767 low risk women receiving traditional prenatal care reported the CenteringPregnancy model was associated with a lower rate of preterm birth &lt;37 weeks (7.9 versus 12.7 percent, P = 0.01) and preterm birth &lt;32 weeks (1.3 versus 3.1 percent, P = 0.03) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/19\">",
"       19",
"      </a>",
"      ]. There were no significant improvements in clinical outcome (eg, low birthweight, neonatal intensive care unit admission) and mean birthweight was larger by only 67 grams. A limitation of this study is that it relied on birth certificate data, which likely underestimated risk factors for preterm birth in the traditional care group. In addition, nulliparous women who received group prenatal care were less likely to smoke cigarettes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Qualitative studies have affirmed these findings and reported higher rates of patient satisfaction, attendance, and knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/2,3,14,15,22-26\">",
"     2,3,14,15,22-26",
"    </a>",
"    ], an increased rate of breastfeeding at hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/24\">",
"     24",
"    </a>",
"    ], and fewer emergency room visits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/2\">",
"     2",
"    </a>",
"    ], although other studies have not found significant benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. One author concluded that both better continuity of provider and community with other women gave women knowledge and power as health care consumers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/25\">",
"     25",
"    </a>",
"    ]. Another concluded that CenteringPregnancy transformed relationships among women, their families, and health care professionals by providing prenatal care that was relationship centered and nurturing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. Thus, group prenatal care may be a more efficient way to deliver prenatal care that provides a richer, more satisfying experience for the participants, but evidence of improved obstetric outcome is more modest and more controversial.",
"   </p>",
"   <p>",
"    Expanded and more rigorous research is needed on the outcomes of group prenatal care and to define the optimal population for this type of care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/30\">",
"     30",
"    </a>",
"    ]. Available studies have largely involved young women of low socioeconomic status; these results may not be generalizable to other populations. It is important to perform more randomized trials to reduce the effect of patient selection bias. It is also important to identify how group care directly or indirectly improves perinatal outcomes, such as preterm birth. Group care programs could also be improved by a better understanding of what types of women choose group care, why they choose it, how they use the group to enhance their pregnancy experience, and how the experience benefited them. Group provider characteristics should also be studied and compared to one-on-one providers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420807\">",
"    <span class=\"h1\">",
"     SELECTION OF WOMEN FOR GROUP PRENATAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group prenatal care was designed to meet the needs of nulliparous and multiparous women with low risk pregnancies who successfully complete the first trimester. As experience with this model accrued, group care has been offered to wider patient populations, including women with HIV, gestational diabetes, substance abuse, and past preterm deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/12,31\">",
"     12,31",
"    </a>",
"    ]. Groups have also been conducted for teens, new immigrants, and incarcerated women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11030/abstract/12\">",
"     12",
"    </a>",
"    ]. Being in a circle of other women provides support for the sharing of issues such as domestic violence that may not otherwise be discussed in a relatively short one-to-one visit. The model also lends itself to care provision in developing countries that struggle with high maternal and infant mortality rates and have fewer resources for providing prenatal care.",
"   </p>",
"   <p>",
"    Some women may find that they are uncomfortable in a group setting and may elect to continue with traditional, one-to-one care. For example, women who have mental illness may find the loose group structure to be difficult for productive participation. Women who know each other because of the tightness of their community may avoid this model of care because they do not want to share personal information with the group. However, CenteringPregnancy groups are very successful in such places as Indian tribal communities and in high school populations where the women know each other and have developed close friendships.",
"   </p>",
"   <p>",
"    The most commonly cited reasons for why women do not enter a group are: scheduling conflicts, childcare issues, lack of transportation, and a strong personal relationship with a specific nonparticipating provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418381\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group prenatal care is built on the premise that some types of health care are most effectively and efficiently provided in groups, which are facilitated rather than taught. It is offered to low risk women who have successfully completed the first trimester, but in many systems, it is offered now as the standard of care. (See",
"      <a class=\"local\" href=\"#H10245776\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1420807\">",
"       'Selection of women for group prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Groups provide a venue for women to meet other women, the support of a community, an opportunity for shared learning and skill-development, and possibly motivation to change behavior. (See",
"      <a class=\"local\" href=\"#H1418594\">",
"       'Designing a system for group prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Groups have 8 to 12 women in them, as well as a",
"      <span class=\"nowrap\">",
"       provider/facilitator",
"      </span>",
"      team, and administrative support. At the first session, 10 two-hour group sessions are scheduled over a six-month period. (See",
"      <a class=\"local\" href=\"#H1418594\">",
"       'Designing a system for group prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women perform and record their own assessments (weight, blood pressure, urine protein, fundal height). (See",
"      <a class=\"local\" href=\"#H1418594\">",
"       'Designing a system for group prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential benefits of group prenatal care include increased efficiency, patient knowledge and satisfaction, fewer late preterm births, and increased breastfeeding rates. (See",
"      <a class=\"local\" href=\"#H28874127\">",
"       'Benefits of group prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Caring for our future: the content of prenatal care. US Public Health Service, Dept of Health &amp; Human Services, Washington, DC 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/2\">",
"      Rising SS. Centering pregnancy. An interdisciplinary model of empowerment. J Nurse Midwifery 1998; 43:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/3\">",
"      Teate A, Leap N, Rising SS, Homer CS. Women's experiences of group antenatal care in Australia--the CenteringPregnancy Pilot Study. Midwifery 2011; 27:138.",
"     </a>",
"    </li>",
"    <li>",
"     Gaudion, A, Menka, Y. No decision about me without me: Centering Pregnancy. The Practising Midwife 2010; 13;15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/5\">",
"      Klima C, Norr K, Vonderheid S, Handler A. Introduction of CenteringPregnancy in a public health clinic. J Midwifery Womens Health 2009; 54:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/6\">",
"      Rising SS, Kennedy HP, Klima CS. Redesigning prenatal care through CenteringPregnancy. J Midwifery Womens Health 2004; 49:398.",
"     </a>",
"    </li>",
"    <li>",
"     Hackley, B, Applebaum, J, Wilcox, W, Arevalo, S. Impact of two scheduling systems on early enrollment in a group prenatal care program. JMWH 2009; 54:168.",
"    </li>",
"    <li>",
"     Centering group care start up. [Cited December 2010]. Available from www.centeringhealthcare.org/pages/centering-model/group-start-up.php.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/9\">",
"      Ickovics JR, Kershaw TS, Westdahl C, et al. Group prenatal care and perinatal outcomes: a randomized controlled trial. Obstet Gynecol 2007; 110:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/10\">",
"      Mooney SE, Russell MA, Prairie B, et al. Group prenatal care: an analysis of cost. J Health Care Finance 2008; 34:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/11\">",
"      Klima CS. Centering pregnancy: a model for pregnant adolescents. J Midwifery Womens Health 2003; 48:220.",
"     </a>",
"    </li>",
"    <li>",
"     Rising, SS, Jolivet, R. Circles of community: the CenteringPregnancy&copy; group prenatal care model. In: Birth Models That Work, Davis-Floyd, R, Barclay, L, Daviss, BA, Tritten, J (Eds), University of California Press, Berkeley and London 2009. P.365.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/13\">",
"      Rising SS, Senterfitt C. Repairing health care: building relationships through groups. Creat Nurs 2009; 15:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/14\">",
"      Novick G, Sadler LS, Knafl KA, et al. The intersection of everyday life and group prenatal care for women in two urban clinics. J Health Care Poor Underserved 2012; 23:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/15\">",
"      Gaudion A, Menka Y. 'No decision about me without me': centering pregnancy. Pract Midwife 2010; 13:15.",
"     </a>",
"    </li>",
"    <li>",
"     DeFrancesco, M, Rising, SS. A new way to be &ldquo;patient-centered&rdquo; and help your practice. The Female Patient 2010; 35:46.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/17\">",
"      Homer CS, Ryan C, Leap N, et al. Group versus conventional antenatal care for women. Cochrane Database Syst Rev 2012; 11:CD007622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/18\">",
"      Ickovics JR, Kershaw TS, Westdahl C, et al. Group prenatal care and preterm birth weight: results from a matched cohort study at public clinics. Obstet Gynecol 2003; 102:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/19\">",
"      Picklesimer AH, Billings D, Hale N, et al. The effect of CenteringPregnancy group prenatal care on preterm birth in a low-income population. Am J Obstet Gynecol 2012; 206:415.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/20\">",
"      Kennedy HP, Farrell T, Paden R, et al. A randomized clinical trial of group prenatal care in two military settings. Mil Med 2011; 176:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/21\">",
"      Barr WB, Aslam S, Levin M. Evaluation of a group prenatal care-based curriculum in a family medicine residency. Fam Med 2011; 43:712.",
"     </a>",
"    </li>",
"    <li>",
"     Skelton, J, Mullins, R, Langston, L, Womack, S, Ebersole, J, Rising, SS, Kovarik, R. Centering Pregnancy Smiles: implementation of a small group prenatal care model with oral health. Journal of Poor and Underserved 2009; 20:545.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/23\">",
"      Massey Z, Rising SS, Ickovics J. CenteringPregnancy group prenatal care: Promoting relationship-centered care. J Obstet Gynecol Neonatal Nurs 2006; 35:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/24\">",
"      Grady MA, Bloom KC. Pregnancy outcomes of adolescents enrolled in a CenteringPregnancy program. J Midwifery Womens Health 2004; 49:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/25\">",
"      Kennedy HP, Farrell T, Paden R, et al. \"I wasn't alone\"--a study of group prenatal care in the military. J Midwifery Womens Health 2009; 54:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/26\">",
"      Baldwin KA. Comparison of selected outcomes of CenteringPregnancy versus traditional prenatal care. J Midwifery Womens Health 2006; 51:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/27\">",
"      Shakespear K, Waite PJ, Gast J. A comparison of health behaviors of women in centering pregnancy and traditional prenatal care. Matern Child Health J 2010; 14:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/28\">",
"      Robertson B, Aycock DM, Darnell LA. Comparison of centering pregnancy to traditional care in Hispanic mothers. Matern Child Health J 2009; 13:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/29\">",
"      Wedin K, Molin J, Crang Svalenius EL. Group antenatal care: new pedagogic method for antenatal care--a pilot study. Midwifery 2010; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/30\">",
"      Sheeder J, Weber Yorga K, Kabir-Greher K. A review of prenatal group care literature: the need for a structured theoretical framework and systematic evaluation. Matern Child Health J 2012; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11030/abstract/31\">",
"      Kershaw TS, Magriples U, Westdahl C, et al. Pregnancy as a window of opportunity for HIV prevention: effects of an HIV intervention delivered within prenatal care. Am J Public Health 2009; 99:2079.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14182 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11030=[""].join("\n");
var outline_f10_49_11030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1418381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10245776\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2481780\">",
"      DESCRIPTION OF GROUP PRENATAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2482445\">",
"      Pilot program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2482452\">",
"      CenteringPregnancy model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1418594\">",
"      Designing a system for group prenatal care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28874127\">",
"      BENEFITS OF GROUP PRENATAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28874143\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1420807\">",
"      SELECTION OF WOMEN FOR GROUP PRENATAL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1418381\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11031="Erythromycin and sulfisoxazole: Pediatric drug information";
var content_f10_49_11031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin and sulfisoxazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/3/23607?source=see_link\">",
"    see \"Erythromycin and sulfisoxazole: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      E.S.P.&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfonamide Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/3/23607?source=see_link\">",
"      see \"Erythromycin and sulfisoxazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dosage recommendation is based on the product's erythromycin content):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &ge;2 months: 40-50 mg/kg/day in divided doses every 6-8 hours; not to exceed 2 g erythromycin or 6 g sulfisoxazole/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 400 mg erythromycin and 1200 mg sulfisoxazole every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral suspension: Erythromycin ethylsuccinate 200 mg and sulfisoxazole acetyl 600 mg per 5 mL (100 mL, 150 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     E.S.P.&reg;: Erythromycin ethylsuccinate 200 mg and sulfisoxazole acetyl 600 mg per 5 mL (100 mL, 150 mL, 200 mL) [cheri beri flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with or without food; shake suspension well before use; maintain adequate fluid intake to prevent crystalluria and kidney stone formation",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted suspension is stable for 14 days when refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections of the upper and lower respiratory tract; otitis media in children caused by susceptible strains of",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     ; other infections in patients allergic to penicillin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pediazole&reg; may be confused with Pediapred&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events specific to this combination have not been identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis, arteritis, cyanosis, edema (including periorbital), flushing, intracranial hypertension, palpitations, periarteritis nodosa, syncope, tachycardia, torsade de pointes, vasculitis, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, depression, disorientation, dizziness, drowsiness, fatigue, fever, hallucinations, headache, insomnia, psychosis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, erythema multiforme, exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter (rare), hypoglycemia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, flatulence, gastrointestinal hemorrhage, glossitis, hypertrophic pyloric stenosis, melena, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, salivary gland swelling, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, clotting disorders (including hypoprothrombinemia, hypofibrinogenemia, sulfhemoglobinemia, methemoglobinemia), eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (including hepatitis, hepatic necrosis, and cholestatic jaundice), liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuritis, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss (reversible), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, blood urea nitrogen increased, crystalluria, diuresis (rare), hematuria, nephritis, serum creatinine increased, toxic nephrosis (with oliguria and anuria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonitis, pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, serum sickness, systemic lupus erythematosus (SLE)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin, any component, or sulfonamides; hepatic dysfunction; infants &lt;2 months of age (sulfas compete with bilirubin for binding sites which may result in kernicterus in newborns); patients with porphyria; pregnant women at term; mothers nursing infants &lt;2 months of age; concomitant administration of astemizole, terfenadine, or cisapride",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal or hepatic function, G-6-PD deficiency (hemolysis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Risk of serious cardiac arrhythmias exist in patients receiving erythromycin, astemizole, terfenadine, or cisapride (do not use concurrently); fatalities due to Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, and aplastic anemia have occurred with the administration of sulfonamides; prolonged use may result in superinfection or pseudomembranous colitis",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Macrolide Antibiotics may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Macrolide Antibiotics may decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Macrolide Antibiotics may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Macrolide Antibiotics may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Macrolide Antibiotics may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Macrolide Antibiotics may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Macrolide Antibiotics may decrease the metabolism of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Macrolide Antibiotics may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Macrolide Antibiotics may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Macrolide Antibiotics may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Macrolide Antibiotics may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Macrolide Antibiotics may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Macrolide Antibiotics may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Macrolide Antibiotics may enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Erythromycin (Systemic) may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Macrolide Antibiotics may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May diminish the therapeutic effect of Erythromycin (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Macrolide Antibiotics may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Macrolide Antibiotics may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifapentine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Erythromycin (Systemic) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Macrolide Antibiotics may decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE; PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary artery hypertension, concurrent use with erythromycin is not recommended.  When used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Erythromycin (Systemic) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Macrolide Antibiotics may decrease the metabolism of Sirolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Erythromycin (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Erythromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Macrolide Antibiotics may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Erythromycin (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit dose of vardenafil film-coated tablets (Levitra)  to 5 mg per 24 hours with concomitant use of erythromycin. Concomitant use of vardenafil orally disintegrating tablets (Staxyn) with erythromycin is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zopiclone: Macrolide Antibiotics may increase the serum concentration of Zopiclone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8500881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination; therefore, the manufacturer classifies erythromycin/sulfisoxazole as pregnancy category C. Erythromycin and sulfisoxazole cross the placenta. Sulfisoxazole is contraindicated in late pregnancy because sulfonamides may cause kernicterus in the newborn. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, urinalysis; periodic liver function and renal function tests; observe patient for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erythromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit; sulfisoxazole competitively inhibits bacterial synthesis of folic acid from para-aminobenzoic acid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Erythromycin ethylsuccinate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: Widely distributed into most body tissues and fluids; poor penetration into CSF; crosses the placenta; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 75% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: In the liver by demethylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: Unchanged drug is excreted and concentrated in bile; &lt;5% of dose eliminated in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Not removed by peritoneal dialysis or hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sulfisoxazole acetyl:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Hydrolyzed in the GI tract to sulfisoxazole which is rapidly and completely absorbed; the small intestine is the major site of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: Into extracellular space; CSF concentration ranges from 8% to 57% of blood concentration in patients with normal meninges; crosses the placenta, excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Undergoes N-acetylation and N-glucuronide conjugation in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life: 4.6-7.8 hours, prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: 50% in urine as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: &gt;50% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13278 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11031=[""].join("\n");
var outline_f10_49_11031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166745\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166746\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047242\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047234\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166734\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166718\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047246\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047238\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047245\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166769\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166766\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047249\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047233\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047232\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166757\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166727\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166730\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8500881\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047241\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047231\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047248\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047240\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13278\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13278|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/3/23607?source=related_link\">",
"      Erythromycin and sulfisoxazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11032="Red marrow normal adult";
var content_f10_49_11032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74577%7EHEME%2F51573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74577%7EHEME%2F51573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of bone marrow in a normal adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These photos illustrate the distribution of erythropoietic (red) marrow in the normal adult, as outlined by uptake of transferrin-bound radioactive iron three hours after injection (scintigram on the left). The patient's body outline is shown in the photo on the right for localization purposes. Erythropoietic marrow is most prominent in the spine (white arrow) and pelvis (red arrow), with lesser amounts in the ribs. There is no uptake of iron in skull, arms, or in the long bones of the legs below the upper portion of the femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Supplied by Stephen A. Landaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of bone marrow in a child with sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The scintigram on the left shows the distribution of erythropoietic (red) marrow in a child with sickle cell disease, as demonstrated by the uptake of transferrin-bound radioactive iron three hours after injection. The child's whole body outline is shown in the photo on the right for localization purposes. Note the marked uptake of isotope in the spine, pelvis, and ribs, a pattern also seen in the adult. Unlike the adult, however, there is also erythropoietic marrow in the skull, jaws, arms, and legs. The latter uptake is most prominent in the region of the knee and ankle joints. The child was not having a painful crisis at the time of this study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Stephen A. Landaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11032=[""].join("\n");
var outline_f10_49_11032=null;
var title_f10_49_11033="Overview of musculoskeletal neck injuries in the young athlete";
var content_f10_49_11033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of musculoskeletal neck injuries in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Jason E Decker, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11033/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/49/11033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of musculoskeletal injuries of the neck in the young athlete will be presented here. The anatomy of the cervical spine, the diagnostic approach to the athlete with neck pain or injury, the prehospital management of the athlete with an acute neck injury, and cervical spinal cord and peripheral nerve injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"     \"Approach to the young athlete with neck pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=see_link\">",
"     \"Field care and evaluation of the young athlete with acute neck injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23689?source=see_link\">",
"     \"Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FRACTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recreational and sports activities are important causes of spinal fractures associated with neurologic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review of 1447 spine fractures treated at two Canadian centers, 14 percent of the fractures, but 23 percent of the injuries with neurologic deficit, were sustained during sporting and recreational activities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/1\">",
"     1",
"    </a>",
"    ]. Among the 202 fractures that occurred during recreational activity, diving accounted for 21 percent, and snowmobiling,",
"    <span class=\"nowrap\">",
"     parachuting/skydiving,",
"    </span>",
"    and equestrian events accounted for 10 percent each. Nearly one-fourth of the fractures were sustained in high-velocity winter sports (eg, snowmobiling, tobogganing, Alpine skiing, and ice hockey).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Atlas (C1) fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial loading of the cervical spine can cause two types of fractures of the atlas, known as Jefferson fractures: posterior arch fractures and burst fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posterior arch fractures are more common (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63483 \" href=\"UTD.htm?37/32/38414\">",
"       image 1",
"      </a>",
"      ); with bracing, they typically heal well with fibrous or bony union.",
"     </li>",
"     <li>",
"      Burst fractures involve disruption of both the anterior and posterior arches, which may allow progressive displacement of the lateral masses of the atlas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66040 \" href=\"UTD.htm?4/59/5041\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef51760 \" href=\"UTD.htm?13/32/13838\">",
"       figure 1",
"      </a>",
"      ), leading to vascular and neurologic compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with Jefferson fractures have neck pain and restricted range of motion of the neck, but they usually have a normal neurologic examination. Prompt and careful evaluation is critical to avoid a delay in diagnosis and secondary neurologic compromise.",
"   </p>",
"   <p>",
"    Open-mouth odontoid views are helpful in establishing the diagnosis. A fracture is suggested by an increased periodontoid space and bilateral symmetrical overhang of the lateral masses of the atlas (C1) in relation to the axis (C2). When the transverse diameter of the atlas is 7 mm greater than that of the axis, a transverse ligament rupture should be suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Subluxation and dislocation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Computed tomography (CT) scans provide excellent detail of the atlas, and are helpful in confirming bony injuries and excluding rupture of the transverse alar ligament (which makes the spine unstable) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, CT scans are recommended in patients in whom C1 fractures are suspected, but whose plain radiographs are normal or inconclusive.",
"   </p>",
"   <p>",
"    The majority of atlas fractures heal with nonoperative immobilization techniques (eg, a halo brace). However, surgical fusion is occasionally necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Axis (C2) fractures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Odontoid fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct head impact can cause fractures of the odontoid (also called the dens), the toothlike projection from the upper surface of the axis (C2). These fractures can occur at the tip or base of the odontoid. Avulsion fractures of the tip are less common, but more stable, whereas fractures of the base have a higher rate of nonunion with nonsurgical treatment.",
"   </p>",
"   <p>",
"    Odontoid fractures usually displace anteriorly with posterior angulation of the dens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/6\">",
"     6",
"    </a>",
"    ]. Displaced odontoid fractures can be identified on lateral radiographs, but nondisplaced fractures and fractures in children may be difficult to visualize. As a general rule, CT scan is recommended in any patient with confirmed or suspected C2 fracture.",
"   </p>",
"   <p>",
"    Similar to atlas fractures, stable odontoid fractures are usually managed nonsurgically. After 6 to 10 weeks of healing, lateral flexion and extension radiographs should be obtained to verify union [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/6\">",
"     6",
"    </a>",
"    ]. Unstable fractures and those that fail to heal satisfactorily require surgical fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/7\">",
"     7",
"    </a>",
"    ]. The prognosis for complete neurologic recovery is good provided that the initial injury does not compromise the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hangman's fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hangman's fracture (spondylolisthesis of C2) is a fracture of the pedicle of the axis, usually resulting from a hyperextension injury. The name is derived from the similar injury suffered during execution-style hangings. Most hangman's fractures result from hyperextension sustained during a motor vehicle accident, but they also occur in diving accidents and headlong falls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite marked anterior displacement of C2 on C3, minimal or no spinal cord injury may result if the victim survives the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hangman's fractures present with neck pain and often have no neurologic symptoms or signs. Diagnosis is established with radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64511 \" href=\"UTD.htm?42/45/43732\">",
"     image 3",
"    </a>",
"    ) and CT.",
"   </p>",
"   <p>",
"    Most cases can be successfully treated with immobilization with a halo vest. Traction alone should be avoided because it increases the potential for nonunion and more serious neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/6\">",
"     6",
"    </a>",
"    ]. Surgical fusion is indicated if there is nonunion or disruption of the C2-C3 disk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cervical compression fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertebral body compression fractures are injuries caused by axial loading with or without cervical flexion or extension. Axial loading occurs when the athlete uses the head in blocking or tackling, or hits the bottom of a body of water after diving into water that is too shallow.",
"   </p>",
"   <p>",
"    The presenting symptoms of compression fractures depend upon the severity as described below. The presentation of mild fractures (types I and II) may be limited to neck pain and cervical spasm. Depending upon the location of the lesion, more severe fractures (types III-V) can cause respiratory arrest and quadriplegia.",
"   </p>",
"   <p>",
"    Most compression fractures are identified by plain radiographs and further clarified by CT. Compression fractures may be classified into five types [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I injuries are simple",
"      <strong>",
"       wedge",
"      </strong>",
"      compression fractures of the cervical vertebrae (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55806 \" href=\"UTD.htm?21/63/22527\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63517 \" href=\"UTD.htm?35/55/36735\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77831 \" href=\"UTD.htm?36/55/37744\">",
"       figure 2",
"      </a>",
"      ). They are stable fractures that heal well with conservative management (8 to 10 weeks in a semirigid cervical collar) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/11\">",
"       11",
"      </a>",
"      ], usually without neurologic sequelae.",
"     </li>",
"     <li>",
"      Type II compression fractures are \"",
"      <strong>",
"       teardrop",
"      </strong>",
"      ,\" or",
"      <strong>",
"       isolated",
"      </strong>",
"      anterior-inferior vertebral body fractures with intact posterior elements (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74721 \" href=\"UTD.htm?1/11/1200\">",
"       image 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef66513 \" href=\"UTD.htm?38/59/39856\">",
"       figure 3",
"      </a>",
"      ). The extension teardrop fracture occurs when abrupt neck extension causes the anterior longitudinal ligament to pull the anteroinferior corner away from the remainder of the vertebral body, producing a triangular-shaped fragment (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62966 \" href=\"UTD.htm?1/54/1903\">",
"       image 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54792 \" href=\"UTD.htm?38/40/39552\">",
"       figure 4",
"      </a>",
"      ). Like type I injuries, most of these injuries are stable and treated conservatively (8 to 10 weeks in a semirigid cervical collar) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. However,",
"      <span class=\"nowrap\">",
"       flexion/extension",
"      </span>",
"      radiographs should be taken after immobilization to evaluate cervical spine stability. In one study of 27 patients with apparently simple compression fractures, six had cervical spine instability diagnosed on follow-up radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type III fractures are",
"      <strong>",
"       comminuted burst",
"      </strong>",
"      vertebral body fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69127 \" href=\"UTD.htm?33/4/33861\">",
"       image 8",
"      </a>",
"      ). The posterior elements remain intact, but bony fragments may be displaced into the spinal medullary canal, resulting in serious neurologic injury. These should be evaluated with CT, and surgical stabilization is needed to prevent late movement of the bone fragments [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"       3",
"      </a>",
"      ]. One variant of this type of fracture is the axial load teardrop fracture. Axial load teardrop fractures must be distinguished from isolated teardrop fractures (described above), which are not usually associated with permanent neurologic sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Types IV and V are complex vertebral fractures involving the posterior elements. They are unstable fractures with a poor prognosis, and often result in quadriplegia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cervical spinous process fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spinous process fracture, also called the clay shoveler's fracture, is an avulsion fracture of the tip of the spinous process, most commonly involving C7 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79308 \" href=\"UTD.htm?40/47/41727\">",
"     image 9",
"    </a>",
"    ). These injuries were classically seen as a result of vigorous labor and forceful contraction of the shoulder muscles. Now they are more commonly seen following trauma from an assault or motor vehicle accident [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractures of the spinous process are typically painful. However, unless they involve the base of the spinous process, these fractures are stable and usually heal well spontaneously. Treatment consists of cervical collar immobilization for pain relief. Range of motion is withheld until the fracture site is nontender (usually within four to six weeks), at which time dynamic radiographs can be performed to evaluate cervical spine stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for return to play after a cervical spine fracture are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H24#H24\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Return to play'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUBLUXATION AND DISLOCATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cervical vertebral subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axial compression combined with cervical flexion, which often occurs when a football player \"spears\" another player with his helmet, can result in cervical vertebral subluxation. The injury occurs to the posterior supporting ligaments, resulting in anterior translation of the superior vertebral body.",
"   </p>",
"   <p>",
"    The patient may complain of neck pain and stiffness, but usually has no neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the imaging modality that best delineates the integrity of ligamentous structures.",
"   </p>",
"   <p>",
"    Flexion-extension views should be obtained if ligamentous injury is suspected despite normal cervical spine radiographs (three views) and MRI is not rapidly available [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the obtunded patient, flexion-extension",
"    <span class=\"nowrap\">",
"     (F/E)",
"    </span>",
"    radiographs perform inadequately in the assessment of blunt cervical spine injury and we do NOT recommend their use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/16\">",
"     16",
"    </a>",
"    ]. In the alert and cooperative patient,",
"    <span class=\"nowrap\">",
"     F/E",
"    </span>",
"    imaging may play a role, particularly if MRI is unavailable. To prevent inadvertent injury to the spinal cord, flexion and extension should be actively performed by the patient in a methodical, slow fashion and only to the point of pain or neurologic symptoms. Findings on flexion-extension views that are consistent with ligamentous injury include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Motion of the vertebral body relative to its position on the plain lateral view (more than 3.5 mm horizontal displacement between adjacent disks)",
"     </li>",
"     <li>",
"      Anterior intervertebral disk-space narrowing",
"     </li>",
"     <li>",
"      Anterior angulation and displacement of the vertebral body",
"     </li>",
"     <li>",
"      Fanning of the spinous processes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any patient who has positive findings on",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    views should undergo MRI imaging and neurosurgical consultation. In addition, MRI may show damage to the supporting posterior soft tissues.",
"   </p>",
"   <p>",
"    Most cases of significant vertebral subluxation require aggressive treatment with posterior cervical fusion to prevent chronic instability and risk of future injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute atlantoaxial instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute atlantoaxial instability (AAI) is usually the result of trauma that forces the neck into extreme flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"     3",
"    </a>",
"    ]. This causes disruption (or rupture) of the transverse ligament of the odontoid process, allowing the odontoid process to move posteriorly and compress the spinal cord.",
"   </p>",
"   <p>",
"    The diagnosis of AAI is made on lateral radiographs of the cervical spine when the space between the posterior aspect of the anterior arch of the atlas and the anterior aspect of the odontoid process is greater than 5 mm in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/17\">",
"     17",
"    </a>",
"    ] and greater than 3 mm in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/18\">",
"     18",
"    </a>",
"    ]. Acute AAI is an unstable injury that requires definitive treatment (ie, posterior fusion of C1 and C2). Patients are usually immobilized for two to three months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAI in children with Down syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Atlantoaxial instability'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of Down syndrome\", section on 'Atlantoaxial instability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atlantoaxial rotary subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atlantoaxial rotary subluxation (Grisel syndrome) is a common form of torticollis seen in children; it is less common in adults. It usually occurs following minor trauma, head and neck surgery, or an upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinical presentation, evaluation, and treatment of atlantoaxial rotary subluxation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link\">",
"     \"Acquired torticollis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Facet dislocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facet dislocation, occurring with or without a fracture, may be unilateral or bilateral. Most of these injuries occur between C-4 and C-7 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Unilateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral facet dislocation is usually caused by an axial loading injury with the neck flexed and rotated (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60285 \" href=\"UTD.htm?14/9/14482\">",
"     image 10",
"    </a>",
"    ). This mechanism results in ligamentous and capsular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/8\">",
"     8",
"    </a>",
"    ]. Facet dislocations that are associated with fractures or that occur at the C3-C4 can cause immediate quadriparesis. Fortunately, most lesions occur lower in the spine and are stable injuries with no neurologic compromise.",
"   </p>",
"   <p>",
"    Uncomplicated unilateral facet dislocations are identified by a lateral radiograph demonstrating an approximately 30 percent anterior shift of the superior vertebra on the inferior vertebra with a sudden obliquity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical traction should be attempted to reduce the dislocation. This procedure should be performed by a surgeon who is experienced in the treatment of cervical spine fractures. If cervical traction is not successful, operative treatment may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bilateral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral facet dislocation is most often caused by forced flexion that results in severe disruption of the ligaments and capsule (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73643 \" href=\"UTD.htm?41/43/42686\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79346 \" href=\"UTD.htm?31/1/31760\">",
"     image 12",
"    </a>",
"    ). This unstable injury usually results in severe neurologic sequelae, including quadriplegia.",
"   </p>",
"   <p>",
"    Lateral radiographs demonstrate anterior translation of approximately one-half of the superior vertebra on the inferior vertebral body with no obliquity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64161 \" href=\"UTD.htm?3/0/3087\">",
"     image 13",
"    </a>",
"    ). These dislocations can usually be reduced by traction, immobilized in a halo cast, and stabilized by posterior fusion of the involved cervical vertebrae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for return to play after ligamentous injuries of the cervical spine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H24#H24\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Return to play'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPEAR TACKLER'S SPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spear tackler's spine, originally described in 1993, is a condition that occurs in football players who habitually tackle using the top of the head as the initial point of contact [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/23\">",
"     23",
"    </a>",
"    ]. Prevention of this condition, which should be emphasized, involves teaching and enforcing proper tackling techniques.",
"   </p>",
"   <p>",
"    Spear tackler's spine is identified by the following radiographic changes (on an erect lateral view with the neck in neutral alignment) in a player who uses the spear tackling technique:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developmental narrowing of the cervical spinal canal",
"     </li>",
"     <li>",
"      Straightening or reversal of the normal cervical lordotic curve (caused by repeated axial loading and microtrauma to the spinal structures)",
"     </li>",
"     <li>",
"      Preexisting minor post-traumatic radiographic evidence of injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spear tackler's spine predisposes the athlete to permanent neurologic injury with continued axial loading [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/23\">",
"     23",
"    </a>",
"    ]. The athlete with spear tackler's spine should be excluded from all",
"    <span class=\"nowrap\">",
"     contact/collision",
"    </span>",
"    sports (",
"    <a class=\"graphic graphic_table graphicRef71147 \" href=\"UTD.htm?17/63/18427\">",
"     table 1",
"    </a>",
"    ), unless the condition is reversed (ie, return of normal cervical lordosis) with appropriate physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/24\">",
"     24",
"    </a>",
"    ]. The rehabilitation program involves relative rest (including exclusion from all",
"    <span class=\"nowrap\">",
"     contact/collision",
"    </span>",
"    sports), modalities such as moist heat and massage, range of motion exercises (including neck and shoulder stretching), and a progressive dynamic and isometric neck strengthening program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CERVICAL DISC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical disc disease is a common cause of neck pain in athletes as well as the general population. The incidence of cervical disc disease increases with age. It typically occurs after the mid-30s, but can occur in younger individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, some sports, including football, wrestling, and rugby, increase the incidence of cervical disc problems over the lifetime of the athlete [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main mechanisms by which a cervical disc causes symptoms: acute disc herniation and degenerative disc disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute disc herniation tends to occur in the younger individual and is more likely to be associated with an identifiable injury. The inciting event may range from a high-impact trauma to simple twisting of the neck during normal daily activities, which causes acute herniation of the nucleus pulposus posterolaterally into the nerve root or spinal cord. The most common areas of disc herniation are the C5-C6 and C6-C7 levels, followed by C4-C5 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The other, more common mechanism of injury is degenerative disc disease. Cervical spondylosis, or narrowing of the neural foramina or spinal canal, results from progressive degeneration of the cervical disc in conjunction with osteophyte formation. These disc changes result in disc space narrowing and bulging or herniation of the degenerative nuclear contents. Secondary osteophytes and spurring at the intervertebral, uncovertebral, and facet joints are caused by the altered mechanics of cervical motion. This process, which is more insidious in onset, tends to occur at the same levels affected by acute disc herniation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of degenerative disc disease is about 10 percent in people in their mid-20s, and progresses linearly to 95 to 100 percent by age 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute disc herniation complain of sudden onset of posterior neck pain. Neck pain may be the only presenting symptom, but some patients have referred pain to the shoulder, periscapular area, arm, or hand, depending upon the location of the disc herniation and the nerve roots involved. More classic neurologic symptoms such as numbness, paresthesias, muscle weakness, and diminished reflexes in the distribution of the affected spinal nerve may also be present (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 2",
"    </a>",
"    ). Patients with spinal cord impingement, which is less common, may have gait disturbance, lower-extremity neurologic symptoms and weakness, or loss of normal",
"    <span class=\"nowrap\">",
"     bowel/bladder",
"    </span>",
"    function. Patients with degenerative disc disease typically have similar symptoms, but a more insidious onset, than those with acute herniation.",
"   </p>",
"   <p>",
"    Physical examination usually reveals a combination of spasm, tenderness, and decreased range of motion of the neck. A neurologic examination of the upper and lower extremities should be performed to locate deficits of sensation (",
"    <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"     figure 5",
"    </a>",
"    ), strength, or reflexes (",
"    <a class=\"graphic graphic_table graphicRef63597 \" href=\"UTD.htm?23/43/24253\">",
"     table 2",
"    </a>",
"    ). The presence of impaired neurologic function helps to localize the lesion. The axial compression and Spurling test (",
"    <a class=\"graphic graphic_picture graphicRef52401 \" href=\"UTD.htm?11/45/11999\">",
"     picture 1",
"    </a>",
"    ) may be positive, exacerbating the patient's neurologic symptoms. Although these tests are specific for radiculopathy, they lack sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link\">",
"     \"Approach to the young athlete with neck pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs of the cervical spine, including oblique views, may help to exclude other conditions. In addition, they may provide some clues to the presence of disc disease including disc space narrowing, foraminal narrowing, or osteophytes.",
"   </p>",
"   <p>",
"    MRI is the study of choice to evaluate cervical disc disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58981 \" href=\"UTD.htm?17/38/18022\">",
"     image 14",
"    </a>",
"    ). It is used to confirm disease when the diagnosis is in question and to plan for invasive treatment such as surgery. MRI abnormalities must be correlated with clinical presentation since MRI evidence of cervical disc disease may be present in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of cervical disc disease can be managed conservatively. Initial treatment consists of pain management and functional improvement with NSAIDS, moist heat, massage, and relative",
"    <span class=\"nowrap\">",
"     rest/activity",
"    </span>",
"    modification.",
"   </p>",
"   <p>",
"    A soft cervical collar may help by providing partial immobilization and a reminder of activity restrictions. Intermittent traction may be useful if radiculopathy is present, particularly if the distraction test (",
"    <a class=\"graphic graphic_picture graphicRef61568 \" href=\"UTD.htm?36/40/37519\">",
"     picture 2",
"    </a>",
"    ) relieves the patient's symptoms.",
"   </p>",
"   <p>",
"    Once pain and function have improved, the patient should begin a physical therapy program for rehabilitation. Improved range of motion and strength of the neck and shoulder muscles are important to the long-term success of treatment. Selective nerve root injections with anesthetic and steroids under fluoroscopy may be a useful adjunct if physical therapy fails to yield acceptable results.",
"   </p>",
"   <p>",
"    Indications for surgical treatment of cervical disc disease include severe neurologic symptoms, failure to improve despite appropriate conservative management, or worsening neurologic symptoms during treatment. In the absence of severe neurologic symptoms, surgery is usually not considered until six to eight weeks of conservative management have failed. Surgical options include laminoforaminotomy with limited disc excision or discectomy and fusion. The latter approach has been shown to relieve radicular symptoms in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to play for athletes with cervical disc disease depends upon the presence of symptoms and, if surgery was necessary, the level and extent of spinal fusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The athlete with symptomatic cervical disc disease must be held out of all contact sports (",
"      <a class=\"graphic graphic_table graphicRef71147 \" href=\"UTD.htm?17/63/18427\">",
"       table 1",
"      </a>",
"      ) until the symptoms have resolved.",
"     </li>",
"     <li>",
"      The athlete may return to play without restrictions if conservative treatment results in complete resolution of pain, restoration of normal painless range of motion, normal strength, and the athlete has no other contraindication to participation (eg, cervical stenosis or spear tackler's spine) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Athletes with single-level fusion may return to play provided the fusion is solid and the patient is asymptomatic. The exception is high-level fusions (C2-C3, C3-C4), which are inherently less stable and more dangerous.",
"     </li>",
"     <li>",
"      Patients with multiple level fusions (particularly of three or more levels) and symptomatic patients should not be permitted to return to contact sports (",
"      <a class=\"graphic graphic_table graphicRef71147 \" href=\"UTD.htm?17/63/18427\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MUSCULAR INJURIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cervical strain/sprain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute strains and sprains of the cervical muscles and ligaments are the most common forms of cervical injury. Isolated strains and sprains do not involve injury to the nerves or bones. They are most often caused by automobile accidents, falls, and injuries sustained in contact-collision sports and recreational activities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with isolated cervical strains or sprains complain of cervical pain without radiation or neurologic symptoms. On examination, they may have limitation of cervical range of motion and muscular spasm or tenderness. The neurologic examination is normal.",
"   </p>",
"   <p>",
"    Because of the potential for dangerous injury to the cervical spine after trauma to the neck, all neck injuries must be evaluated with diligence and caution. An athlete who has worrisome symptoms or findings on physical examination (",
"    <a class=\"graphic graphic_table graphicRef76379 \" href=\"UTD.htm?20/20/20811\">",
"     table 3",
"    </a>",
"    ) after an acute neck injury should have his or her cervical spine immobilized until radiographic evaluation is complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the patient with a cervical",
"    <span class=\"nowrap\">",
"     strain/sprain",
"    </span>",
"    should be individualized based upon the severity of the patient's symptoms. Initial treatment for pain reduction includes",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NSAIDs and modalities such as moist heat and ultrasound. When pain and range of motion have improved, management should focus on rehabilitation deficits in strength as flexibility. If symptoms persist, further evaluation with MRI may be indicated to evaluate other causes of neck pain such as disc herniation. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Cervical disc disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the young athlete with neck pain or injury\", section on 'Strength testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Return to play",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with complaints of neck pain in the absence of other red flags for an unstable cervical spine injury (",
"    <a class=\"graphic graphic_table graphicRef76379 \" href=\"UTD.htm?20/20/20811\">",
"     table 3",
"    </a>",
"    ) should be excluded from play until he or she is asymptomatic with normal range of motion and strength. Even mildly symptomatic posttraumatic neck pain or decreased range of motion should be evaluated with radiographs including flexion and extension views to rule out significant injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Whiplash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whiplash is a relatively common but still poorly understood neck injury; the incidence is about 4 per 1000 persons [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/33\">",
"     33",
"    </a>",
"    ]. Whiplash has been defined as an acceleration-deceleration injury to the cervical spine most commonly caused by motor vehicle accidents, specifically from rear-end or side impact [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/34\">",
"     34",
"    </a>",
"    ]. Such injuries may also occur in football, hockey, and rugby players. The mechanism of injury seems to be strong compressive and translational forces on the joints and soft tissues, resulting in an abnormal S-shaped movement pattern of the lower cervical spine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients typically present with head, neck, and upper thoracic pain and decreased range of motion. The symptoms occur at the time of injury, and they may continue to worsen over the following 48 hours. This delayed worsening of symptoms often prompts the patient to seek treatment several days after the injury. They may have cervical muscle spasm, but neurologic signs and symptoms are usually lacking. Symptoms are often out of proportion to objective findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest that whiplash is more akin to a functional disorder that is often encouraged by economic gains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The most common radiographic findings are preexisting degenerative changes or decreased lordosis of the cervical spine secondary to spasm and disuse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/39\">",
"     39",
"    </a>",
"    ]. CT and MRI are generally reserved for patients with neurologic deficit or suspected damage to the spinal cord, discs, bones, or ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whiplash injuries can be difficult to treat because the injury is often ill-defined and difficult to characterize by physical examination and radiographic evidence. Studies suggest that early treatment can significantly improve both short-term and long-term morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/41\">",
"     41",
"    </a>",
"    ]. A comprehensive approach with the goals of early pain control and functional improvement seem to work better than the traditional model of immobilization with a soft collar [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/42\">",
"     42",
"    </a>",
"    ]. Such a program would include analgesia with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , NSAIDs, modalities such as moist heat, and physical therapy to improve strength and range of motion. In selected patients with physiologically unexplainable chronic pain, consultation with a mental health care provider may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     POSTURAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor posture is a common contributing factor for, if not the cause of, nonspecific neck pain in people of all ages. The problematic posture may be occupational (poor office ergonomics), sport-specific (cycling, baseball catchers), caused by muscle imbalance, or simply the result of bad habits.",
"   </p>",
"   <p>",
"    The patient may complain of periscapular or posterior neck pain that is exacerbated by prolonged static posture. Headaches are a common feature.",
"   </p>",
"   <p>",
"    On physical examination, typical features of postural syndromes include (",
"    <a class=\"graphic graphic_picture graphicRef57310 \" href=\"UTD.htm?36/37/37470\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11033/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thoracic kyphosis",
"     </li>",
"     <li>",
"      Rounded shoulders",
"     </li>",
"     <li>",
"      Tight pectoral muscles",
"     </li>",
"     <li>",
"      Restricted shoulder movements",
"     </li>",
"     <li>",
"      Protruding chin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the postural features, the patient often has poor segmental movement of the cervical and thoracic vertebrae. The affected cervical or scapula stabilizing muscles may be tender to palpation and may contain trigger points. Weakness of the periscapular muscles and abnormal scapulothoracic movement may be noted.",
"   </p>",
"   <p>",
"    Treatment must be individualized, depending upon the clinical features and etiologic mechanism. A comprehensive approach, as outlined below, is helpful in addressing biomechanical causes of neck and upper back pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postural retraining is of the utmost importance. Having the patient concentrate on chin tucks and the \"chest out\" position will help to improve mechanics and may improve the symptoms. Postural retraining requires consultation with a physical therapist who can demonstrate a therapy program that is designed to be performed by the patient at home each day.",
"     </li>",
"     <li>",
"      Workplace modifications may be simple and effective.",
"     </li>",
"     <li>",
"      Physical therapy for mobilization, myofascial release, stretching of the shoulder capsule and pectoral muscles, and neuromuscular retraining will help to improve range of motion and encourage more balanced muscle use patterns.",
"     </li>",
"     <li>",
"      Taping techniques, demonstrated by a physical therapist, can serve to remind the patient to use the correct muscles while maintaining sound posture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13013309\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of musculoskeletal neck injuries may accompany sports participation in the young athlete and management varies depending upon the specific injury. Potential injuries include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical spine fractures (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical spine subluxation or dislocation (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Subluxation and dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spear tackler&rsquo;s spine (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Spear tackler's spine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical disc disease (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Cervical disc disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle injuries (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Muscular injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postural syndromes (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Postural syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiologic evaluation of cervical spine injuries in the young athlete is determined by history and physical examination (",
"      <a class=\"graphic graphic_table graphicRef79881 \" href=\"UTD.htm?9/11/9405\">",
"       table 4",
"      </a>",
"      ) and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Athletes with persistent clinical findings after diagnosis of spear tackler&rsquo;s spine, cervical disc disease, or muscular injuries should be restricted from",
"      <span class=\"nowrap\">",
"       contact/collision",
"      </span>",
"      sports (",
"      <a class=\"graphic graphic_table graphicRef71147 \" href=\"UTD.htm?17/63/18427\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Spear tackler's spine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Cervical disc disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Muscular injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Return to play for young athletes with cervical spine fractures, subluxations, or dislocations is discussed separately (",
"      <a class=\"graphic graphic_table graphicRef65756 \" href=\"UTD.htm?29/5/29789\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef77229 \" href=\"UTD.htm?30/33/31261\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=see_link&amp;anchor=H24#H24\">",
"       \"Approach to the young athlete with neck pain or injury\", section on 'Return to play'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/1\">",
"      Reid DC, Saboe L. Spine fractures in winter sports. Sports Med 1989; 7:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/2\">",
"      Jefferson, G. Fracture of the atlas vertebra. Br J Surg 1920; 7:407.",
"     </a>",
"    </li>",
"    <li>",
"     DeLee and Drez's Orthopaedic Sports Medicine: Principles and Practice, 2nd, DeLee, JC, Drez, D (Eds), WB Saunders, St. Louis 2003. p.791.",
"    </li>",
"    <li>",
"     Tachdjian, MO. The neck and upper limb. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton &amp; Lange, Stamford 1997. p.263.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/5\">",
"      Hadley MN, Dickman CA, Browner CM, Sonntag VK. Acute traumatic atlas fractures: management and long term outcome. Neurosurgery 1988; 23:31.",
"     </a>",
"    </li>",
"    <li>",
"     Loder, RT. The cervical spine. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissy, RT, Weinstein, SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.900.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/7\">",
"      Hadley MN, Dickman CA, Browner CM, Sonntag VK. Acute axis fractures: a review of 229 cases. J Neurosurg 1989; 71:642.",
"     </a>",
"    </li>",
"    <li>",
"     Emergency Management of Skeletal Injuries, Ruiz, E, Cicero, JJ (Eds), Mosby, St. Louis 1995. p.71.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/9\">",
"      Francis WR, Fielding JW. Traumatic spondylolisthesis of the axis. Orthop Clin North Am 1978; 9:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/10\">",
"      Allen BL Jr, Ferguson RL, Lehmann TR, O'Brien RP. A mechanistic classification of closed, indirect fractures and dislocations of the lower cervical spine. Spine (Phila Pa 1976) 1982; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/11\">",
"      Zmurko MG, Tannoury TY, Tannoury CA, Anderson DG. Cervical sprains, disc herniations, minor fractures, and other cervical injuries in the athlete. Clin Sports Med 2003; 22:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/12\">",
"      KAHN EA, SCHNEIDER RC. Chronic neurological sequelae of acute trauma to the spine and spinal cord. I. The significance of the acute-flexion or tear-drop fracture-dislocation of the cervical spine. J Bone Joint Surg Am 1956; 38-A:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/13\">",
"      Mazur JM, Stauffer ES. Unrecognized spinal instability associated with seemingly \"simple\" cervical compression fractures. Spine (Phila Pa 1976) 1983; 8:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/14\">",
"      Meredith RM, Butcher JD. Field splinting of suspected fractures: preparation, assessment, and application. Phys Sportsmed 1997; 25:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/15\">",
"      Lewis LM, Docherty M, Ruoff BE, et al. Flexion-extension views in the evaluation of cervical-spine injuries. Ann Emerg Med 1991; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/16\">",
"      Crim JR, Moore K, Brodke D. Clearance of the cervical spine in multitrauma patients: the role of advanced imaging. Semin Ultrasound CT MR 2001; 22:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/17\">",
"      FIELDING JW. Cineroentgenography of the normal cervical spine. J Bone Joint Surg Am 1957; 39-A:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/18\">",
"      Graber MA, Kathol M. Cervical spine radiographs in the trauma patient. Am Fam Physician 1999; 59:331.",
"     </a>",
"    </li>",
"    <li>",
"     Lovell and Winter's Pediatric Orthopaedics, 5th, Morrissy, RT, Weinstein, SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/20\">",
"      Fife D, Kraus J. Anatomic location of spinal cord injury. Relationship to the cause of injury. Spine (Phila Pa 1976) 1986; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/21\">",
"      Funk FF, Wells RE. Injuries of the cervical spine in football. Clin Orthop Relat Res 1975; :50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/22\">",
"      Kewalramani LS, Krauss JF. Cervical spine injuries resulting from collision sports. Paraplegia 1981; 19:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/23\">",
"      Torg JS, Sennett B, Pavlov H, et al. Spear tackler's spine. An entity precluding participation in tackle football and collision activities that expose the cervical spine to axial energy inputs. Am J Sports Med 1993; 21:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/24\">",
"      Cantu RC, Bailes JE, Wilberger JE Jr. Guidelines for return to contact or collision sport after a cervical spine injury. Clin Sports Med 1998; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/25\">",
"      Kelsey JL, Githens PB, Walter SD, et al. An epidemiological study of acute prolapsed cervical intervertebral disc. J Bone Joint Surg Am 1984; 66:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/26\">",
"      Albright JP, Moses JM, Feldick HG, et al. Nonfatal cervical spine injuries in interscholastic football. JAMA 1976; 236:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/27\">",
"      Scher AT. Premature onset of degenerative disease of the cervical spine in rugby players. S Afr Med J 1990; 77:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/28\">",
"      Scherping SC Jr. Cervical disc disease in the athlete. Clin Sports Med 2002; 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/29\">",
"      Lawrence JS. Disc degeneration. Its frequency and relationship to symptoms. Ann Rheum Dis 1969; 28:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/30\">",
"      Boden SD, McCowin PR, Davis DO, et al. Abnormal magnetic-resonance scans of the cervical spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am 1990; 72:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/31\">",
"      Bohlman HH, Emery SE, Goodfellow DB, Jones PK. Robinson anterior cervical discectomy and arthrodesis for cervical radiculopathy. Long-term follow-up of one hundred and twenty-two patients. J Bone Joint Surg Am 1993; 75:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/32\">",
"      Versteegen GJ, Kingma J, Meijler WJ, ten Duis HJ. Neck sprain not arising from car accidents: a retrospective study covering 25 years. Eur Spine J 1998; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/33\">",
"      Barnsley L, Lord S, Bogduk N. Whiplash injury. Pain 1994; 58:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/34\">",
"      Spitzer WO, Skovron ML, Salmi LR, et al. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining \"whiplash\" and its management. Spine (Phila Pa 1976) 1995; 20:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/35\">",
"      Grauer JN, Panjabi MM, Cholewicki J, et al. Whiplash produces an S-shaped curvature of the neck with hyperextension at lower levels. Spine (Phila Pa 1976) 1997; 22:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/36\">",
"      Ferrari R. Whiplash--review of a commonly misunderstood injury. Am J Med 2002; 112:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/37\">",
"      Cassidy JD, Carroll LJ, C&ocirc;t&eacute; P, et al. Effect of eliminating compensation for pain and suffering on the outcome of insurance claims for whiplash injury. N Engl J Med 2000; 342:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/38\">",
"      Schrader H, Obelieniene D, Bovim G, et al. Natural evolution of late whiplash syndrome outside the medicolegal context. Lancet 1996; 347:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/39\">",
"      Voyvodic F, Dolinis J, Moore VM, et al. MRI of car occupants with whiplash injury. Neuroradiology 1997; 39:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/40\">",
"      Van Geothem JW, Biltjes IG, van den Hauwe L, et al. Whiplash injuries: is there a role for imaging? Eur J Radiol 1996; 22:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/41\">",
"      Rosenfeld M, Gunnarsson R, Borenstein P. Early intervention in whiplash-associated disorders: a comparison of two treatment protocols. Spine (Phila Pa 1976) 2000; 25:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11033/abstract/42\">",
"      Borchgrevink GE, Kaasa A, McDonagh D, et al. Acute treatment of whiplash neck sprain injuries. A randomized trial of treatment during the first 14 days after a car accident. Spine (Phila Pa 1976) 1998; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     Brukner, P, Khan, K. Clinical Sports Medicine, 2nd, McGraw-Hill, Sydney 2000.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6531 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11033=[""].join("\n");
var outline_f10_49_11033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13013309\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Atlas (C1) fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Axis (C2) fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Odontoid fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hangman's fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cervical compression fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cervical spinous process fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUBLUXATION AND DISLOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cervical vertebral subluxation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute atlantoaxial instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atlantoaxial rotary subluxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Facet dislocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Unilateral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bilateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPEAR TACKLER'S SPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CERVICAL DISC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MUSCULAR INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cervical strain/sprain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Return to play",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Whiplash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      POSTURAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13013309\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6531|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/32/38414\" title=\"diagnostic image 1\">",
"      C1 fracture posterior neural arch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/59/5041\" title=\"diagnostic image 2\">",
"      Jefferson fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/45/43732\" title=\"diagnostic image 3\">",
"      Hangmans fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/63/22527\" title=\"diagnostic image 4\">",
"      Cervical wedge fracture close up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/55/36735\" title=\"diagnostic image 5\">",
"      Cervical wedge fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/11/1200\" title=\"diagnostic image 6\">",
"      Cervical flexion teardrop fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/54/1903\" title=\"diagnostic image 7\">",
"      Cervical extension teardrop fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/4/33861\" title=\"diagnostic image 8\">",
"      Burst fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/47/41727\" title=\"diagnostic image 9\">",
"      Spinous process fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/9/14482\" title=\"diagnostic image 10\">",
"      Unilateral facet dislocation CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/43/42686\" title=\"diagnostic image 11\">",
"      Bilateral facet dislocation xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/1/31760\" title=\"diagnostic image 12\">",
"      Bilateral facet dislocation CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/0/3087\" title=\"diagnostic image 13\">",
"      Bilateral facet dislocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/38/18022\" title=\"diagnostic image 14\">",
"      Cervical disc herniation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6531|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/32/13838\" title=\"figure 1\">",
"      C1 burst fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/55/37744\" title=\"figure 2\">",
"      Vertebral anterior wedge fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/59/39856\" title=\"figure 3\">",
"      Vertebral flexion teardrop fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/40/39552\" title=\"figure 4\">",
"      Vertebral extension teardrop fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 5\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6531|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/45/11999\" title=\"picture 1\">",
"      Spurling test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/40/37519\" title=\"picture 2\">",
"      Manual vertical traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/37/37470\" title=\"picture 3\">",
"      Slumped posture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/63/18427\" title=\"table 1\">",
"      Contact collision sports",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/43/24253\" title=\"table 2\">",
"      Neurologic deficits in spinal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/20/20811\" title=\"table 3\">",
"      Signs and symptoms of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/11/9405\" title=\"table 4\">",
"      Radiologic evaluation of the C spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/5/29789\" title=\"table 5\">",
"      Return to play guidelines A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/33/31261\" title=\"table 6\">",
"      Return to play guidelines B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41368?source=related_link\">",
"      Approach to the young athlete with neck pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15815?source=related_link\">",
"      Field care and evaluation of the young athlete with acute neck injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=related_link\">",
"      Management of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23689?source=related_link\">",
"      Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11034="Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency";
var content_f10_49_11034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Deborah P Merke, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/49/11034/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/49/11034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This conversion is mediated by 21-hydroxylase, the enzyme encoded by the",
"    <em>",
"     CYP21A2",
"    </em>",
"    gene.",
"   </p>",
"   <p>",
"    Patients with \"classic\" or the most severe form of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency present during the neonatal period and early infancy with adrenal insufficiency with or without salt-losing, or as toddlers with virilization. Females have genital ambiguity.",
"   </p>",
"   <p>",
"    \"Nonclassic,\" or late-onset 21-hydroxylase deficiency, presents later in life with signs of androgen excess, and without neonatal genital ambiguity. Clinical features in childhood may include premature pubarche, and accelerated bone age; adolescent and adult females may present with hirsutism, menstrual irregularity, infertility, and acne. Some patients with nonclassic CAH remain asymptomatic.",
"   </p>",
"   <p>",
"    The pathophysiology, genetics, and clinical manifestations of congenital adrenal hyperplasia due to",
"    <em>",
"     CYP21A2",
"    </em>",
"    mutations will be reviewed here. The diagnosis and treatment of classic 21-hydroxylase deficiency in adults and in children, and an overview of nonclassic congenital adrenal hyperplasia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon neonatal screening studies that detect classic CAH, 21-hydroxylase deficiency is one of the more common inherited disorders. Data from approximately 6.5 million newborn infants screened worldwide shows an estimate of approximately 1 in 15,000 livebirths [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Prevalence varies according to ethnicity and geographic area. This number varies from as low as 1 in 28,000 in the Chinese population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/6\">",
"     6",
"    </a>",
"    ], to 1 in 5000 to 23,000 live births in Caucasian [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], to as high as 1 in 280 in Yupik Eskimos in Alaska [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/9\">",
"     9",
"    </a>",
"    ] and 1 in 2100 in the French island of La Reunion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the prevalence is lower in African-Americans than in Caucasians (1 in 42,000 versus 1 in 15,500, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 67 percent of classic patients are classified as \"salt-losing,\" while 33 percent of classic patients have \"non-salt-losing\" or the \"simple-virilizing\" form, reflecting the degree of aldosterone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nonclassic form is one of the most common autosomal recessive diseases, and the frequency is ethnic-specific. Among Caucasians, the prevalence of these forms of the disorder may be as high as 1 in 1000 to 1 in 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], with the prevalence being even higher among Mediterraneans, Hispanics, Yugoslavs, and Eastern European Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients with the nonclassic form will not be identified by standard screening studies because they are based upon detection of very high levels of 17-hydroxyprogesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/12\">",
"     12",
"    </a>",
"    ]. The frequency of heterozygote carriers has been reported to be about 1 in 60 to 80 in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/6,9\">",
"     6,9",
"    </a>",
"    ], but closer to 1 in 10 in another study using mutation analysis in a European population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol in patients with 21-hydroxylase deficiency results in decreased cortisol synthesis and therefore increased corticotropin (ACTH) secretion (",
"    <a class=\"graphic graphic_figure graphicRef81907 \" href=\"UTD.htm?1/15/1278\">",
"     figure 1",
"    </a>",
"    ). The resulting adrenal stimulation leads to increased production of androgens. The severity of disease relates to the degree to which the mutations compromise enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Genotype versus phenotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the other forms of congenital adrenal hyperplasia, 21-hydroxylase deficiency is transmitted as an autosomal recessive disorder. There may be a survival advantage for heterozygote carriers who have a small, but significantly greater adrenal response to ACTH than normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans have two",
"    <em>",
"     CYP21A",
"    </em>",
"    genes, a non-functional pseudogene (",
"    <em>",
"     CYP21A1",
"    </em>",
"    or",
"    <em>",
"     CYP21P",
"    </em>",
"    ) and the active gene (",
"    <em>",
"     CYP21A2",
"    </em>",
"    or",
"    <em>",
"     CYP21",
"    </em>",
"    ), both located in a 35-kilobase region of chromosome 6p21.3 within the major histocompatibility locus&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. The pseudogene produces a truncated enzyme with no activity because it lacks eight bases from codons 110-112, resulting in a stop codon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two",
"    <em>",
"     CYP21A",
"    </em>",
"    genes are more than 90 percent homologous. This high degree of homology facilitates recombination events during meiosis, with consequent exchanges of segments of DNA between the two genes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unequal cross-over exchanges leading to deletions of large segments of the",
"      <em>",
"       CYP21P",
"      </em>",
"      gene or a non-functioning",
"      <span class=\"nowrap\">",
"       <em>",
"        CYP21P/CYP21",
"       </em>",
"      </span>",
"      fusion gene (macroconversion) account for about 20 percent of",
"      <em>",
"       CYP21A2",
"      </em>",
"      mutations described to date [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1,7,20\">",
"       1,7,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other hybrid",
"      <span class=\"nowrap\">",
"       <em>",
"        CYP21A1/CYP21A2",
"       </em>",
"      </span>",
"      gene products have decreased, not absent, enzyme activity. A patient who is heterozygous for this and a typical large gene deletion may have nonclassic 21-hydroxylase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Altered regions of the",
"      <em>",
"       CYP21A1",
"      </em>",
"      gene can be transferred to the",
"      <em>",
"       CYP21A2",
"      </em>",
"      gene though non-reciprocal gene conversion. This is a process by which a segment of genetic material is transferred to a closely related gene, altering its sequence [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These microconversion events represent acquisition of smaller segments of the",
"      <em>",
"       CYP21A1",
"      </em>",
"      sequence by the",
"      <em>",
"       CYP21A2",
"      </em>",
"      gene and result in deleterious point mutations that reduce enzyme activity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/3,18-20\">",
"       3,18-20",
"      </a>",
"      ]. They are present in about 70 percent of patients with defined genetic abnormalities.",
"     </li>",
"     <li>",
"      Eighteen such gene conversion mutations account for nearly all affected alleles in various ethnic groups [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/3,24-26\">",
"       3,24-26",
"      </a>",
"      ]. The remaining 5 percent of patients with defined abnormalities have one or more of the 60 point mutations thus far identified, most being compound heterozygotes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/3,26-31\">",
"       3,26-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among 130 Brazilian patients, 20 percent did not have a known mutation, suggesting that other mutations occur. A novel missense mutation was subsequently identified in three patients with suggestion of a founder effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/26\">",
"     26",
"    </a>",
"    ]. No mutation was detected in the entire coding region of the gene and up to 1 kb of the 5'-flanking promoter region of the gene in a Mexican and three Japanese patients, suggesting that more distant mutations may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a second series of 182 unrelated patients with 21-hydroxylase deficiency, targeted CP21A2 mutation analysis failed to identify mutations in 19 patients (10.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/34\">",
"     34",
"    </a>",
"    ]. On more extensive analysis, novel mutations and previously reported rare mutations were identified in 18 of the 19 subjects: nine previously reported mutations were identified in 12 probands and six novel mutations were identified in six probands (eg, 15 mutations in 18 patients).",
"   </p>",
"   <p>",
"    Genotypically, women with the nonclassic form may be either compound heterozygotes (with a classic mutation and a variant allele) or homozygous with two variant alleles. Relatives of women with this attenuated form may have similar biochemical abnormalities, but no signs of androgen excess. Women who carry the classic (severe) mutation have an increased risk of giving birth to a child with classic adrenal hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genotype versus phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the",
"    <em>",
"     CYP21A2",
"    </em>",
"    gene, but there are general correlations between genotype and phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/3,11,27-30,35-42\">",
"     3,11,27-30,35-42",
"    </a>",
"    ]. Patients with",
"    <em>",
"     CYP21A2",
"    </em>",
"    mutations can be divided into groups according to the predicted effect of the mutation on 21-hydroxylase enzymatic activity, as determined by site-directed mutagenesis and expression and in vitro analysis of enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The salt-losing form of the disorder is most often associated with large deletions or intron 2 mutations that affect splicing and result in no enzyme activity.",
"     </li>",
"     <li>",
"      Patients with simple virilizing form have low but detectable enzyme activity (ie, 1 to 2 percent) that supports sufficient aldosterone and glucocorticoid production. This most commonly results from point mutations leading to nonconservative amino-acid substitutions such as Ile172Asp.",
"     </li>",
"     <li>",
"      Women with the nonclassic form may be either compound heterozygotes (with a classic mutation and a variant allele) or heterozygotes with two variant alleles, allowing for 20 to 60 percent of normal enzymatic activity (eg, with point mutations leading to conservative amino acid substitutions such as Val281Leu).",
"     </li>",
"     <li>",
"      Patients who are compound heterozygotes for two different",
"      <em>",
"       CYP21A2",
"      </em>",
"      mutations usually have the phenotype associated with the less severe of the two genetic defects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/24\">",
"       24",
"      </a>",
"      ]. Heterozygotes may have mild biochemical abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/15,43,44\">",
"       15,43,44",
"      </a>",
"      ], but no clinically important endocrine disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these general correlations, the",
"    <em>",
"     CYP21A2",
"    </em>",
"    mutation phenotype does not always correlate precisely with the genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/8,29,30\">",
"     8,29,30",
"    </a>",
"    ], suggesting that other genes influence the clinical manifestations. In general, there appear to be high concordance rates between genotype and phenotype in patients with the most severe and the mildest forms of the disease, but less genotype-phenotype correlation in moderately affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/27,28,39,40\">",
"     27,28,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of disease ranges from the most severe to mild forms, depending on the degree of 21-hydroxylase deficiency. Three main clinical phenotypes have been described: classic salt-losing, classic non-salt-losing (simple-virilizing), and nonclassic (late-onset):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Females with the classic form (salt-losing and non-salt-losing) present with genital ambiguity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Males with the salt-losing form who are not identified by neonatal screening present with failure to thrive, dehydration, hyponatremia, and hyperkalemia typically at 7 to 14 days of life.",
"     </li>",
"     <li>",
"      Males with the classic non-salt-losing form who are not identified by neonatal screening typically present at two to four years of age with early virilization (pubic hair, growth spurt, adult body odor).",
"     </li>",
"     <li>",
"      Nonclassic or late-onset 21-hydroxylase deficiency may present as hirsutism and menstrual irregularity in young women, early pubarche or sexual precocity in school age children, or there may be no symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"       \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infants/children",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ambiguous genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female infants with classic 21-hydroxylase deficiency are born with ambiguous genitalia. Female newborns have clitoral enlargement (",
"    <a class=\"graphic graphic_picture graphicRef64870 \" href=\"UTD.htm?18/52/19266\">",
"     picture 1",
"    </a>",
"    ), labial fusion, and formation of a urogenital sinus caused by the effects of androgen excess on development of the external genitalia in utero. Rarely, genital ambiguity may be so profound that inappropriate sex assignment is made at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected males are normal appearing at birth, but may have subtle findings such as hyperpigmentation of the scrotum or an enlarged phallus.",
"   </p>",
"   <p>",
"    The surgical management of children born with ambiguous genitalia is complex. The Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology recommend that surgery should be done in virilized girls with classic CAH at age two to six months because it is technically easier than at a later age.",
"   </p>",
"   <p>",
"    Surgery should be done only in medical centers with substantial experience, and management ideally should be done by a multidisciplinary team that includes specialists in pediatric endocrinology, pediatric surgery, urology, psychosocial services, and genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/45\">",
"     45",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Current approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal diagnosis of",
"    <em>",
"     CYP21A2",
"    </em>",
"    deficiency and prenatal treatment of affected offspring are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Prenatal diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Prenatal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with CAH are at risk for early puberty and adult short stature. Exposure to high levels of sex hormones can induce early puberty and premature epiphyseal closure. Excess glucocorticoid exposure secondary to treatment may also suppress growth and contribute to adult short stature.",
"   </p>",
"   <p>",
"    Retrospective studies have shown that the final height of treated patients is independent of the degree of control of adrenal androgen concentrations, suggesting that both hyperandrogenism and hypercortisolism play a role in the observed short stature. A meta-analysis of data from 18 centers showed that the mean adult height of patients with classic CAH was 1.4 standard deviations (10 cm) below the population mean [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with nonclassic CAH have a more favorable height prognosis but are also at risk for loss of adult height. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sexual behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of female patients with classic congenital adrenal hyperplasia suggest that exposure to excess androgens during prenatal development may influence the brain as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female patients with classic congenital adrenal hyperplasia have more male-typical childhood play than unaffected girls [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/47,48\">",
"       47,48",
"      </a>",
"      ] and have more interest in male-typical activities and careers [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report, 31 women with congenital adrenal hyperplasia (mean age 25 years) recalled more cross-gender role behavior and fewer sexual experiences with men than 15 unaffected relatives of the same age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/50\">",
"       50",
"      </a>",
"      ]. In contrast, there was no difference in the relationship status between the two groups (eg,",
"      <span class=\"nowrap\">",
"       married/cohabitating",
"      </span>",
"      versus single).",
"     </li>",
"     <li>",
"      Adolescent and adult women with congenital adrenal hyperplasia may have greater aggressive tendencies than unaffected healthy women [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overall, patients with CAH have favorable quality-of-life [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/53\">",
"       53",
"      </a>",
"      ] and good psychological health [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of 21-hydroxylase deficiency on cognitive function is uncertain. Some studies suggest that patients with the most severe form of 21-hydroxylase deficiency and those who have experienced salt-losing adrenal crises with abnormal electrolytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoglycemia as neonates are at risk for cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/55\">",
"     55",
"    </a>",
"    ]. This was illustrated in a study of 35 Danish women with congenital adrenal hyperplasia and healthy age-matched controls undergoing testing with the Wechsler Adult Intelligence Scale (WAIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/56\">",
"     56",
"    </a>",
"    ]. Women with CAH had significantly lower intelligence quotients (IQ) compared with controls (mean full-scale IQ 84.5 versus 99.1 and mean performance IQ 85.7 versus 101.3 in the CAH and control women, respectively). The salt-losing group had the lowest IQ scores.",
"   </p>",
"   <p>",
"    Surprisingly, an IQ advantage has also been reported in a number of studies of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/57\">",
"     57",
"    </a>",
"    ], possibly due to socioeconomic, genetic, or hormonal factors.",
"   </p>",
"   <p>",
"    Some data have suggested that girls with CAH develop a more male-typical cognitive pattern (better performance on spatial tasks, worse performance on verbal tasks) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, in a study of 24 women with salt-losing or simple virilizing 21-hydroxylase deficiency undergoing detailed cognitive testing, there were no differences in overall IQ, visuospatial processing, or verbal learning and memory, suggesting that prenatal androgen exposure does not have an organizing effect on female cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, 54 patients with CAH underwent a virtual water maze test that measures spatial cognition and has established performance sex-differences in healthy controls. Females with the most severe salt-wasting form of CAH and patients with advanced bone age during childhood displayed improved performance, similar to healthy males, suggesting that both in utero and long-term childhood exposure to excess testosterone has long-lasting effects on cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Female reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility rates in women with classic forms of 21-hydroxylase deficiency are low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/62\">",
"     62",
"    </a>",
"    ]. Possible contributing factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperandrogenemia due to inadequate glucocorticoid therapy, thereby resulting in anovulatory cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/62-66\">",
"       62-66",
"      </a>",
"      ]. The androgen excess is not simply due to ACTH hypersecretion; other factors include mild hyperresponsiveness of ACTH to corticotropin-releasing hormone stimulation, reduced catalytic activity of the 21-hydroxylase enzyme, and abnormal gonadotropin dynamics with excess ovarian production of progesterone, 17-hydroxyprogesterone, and androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Structural factors related to genital malformations or suboptimal surgical reconstruction may leave the vaginal introitus inadequate, and may contribute to impaired reproductive self-image [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fertility rates are related to the severity of the mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/69\">",
"       69",
"      </a>",
"      ]. Pregnancy rates of 60 to 80 percent and 7 to 60 percent of women have been reported in women with classic non-salt-losing and classic salt-losing CAH, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/62,66\">",
"       62,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women with classic 21-hydroxylase deficiency who do conceive, their unaffected female offspring do not have genital virilization, but careful management with monitoring of androgen levels during gestation is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adrenal rest tumors in the ovary are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/71\">",
"     71",
"    </a>",
"    ], unlike in male patients, who often have testicular adrenal rest tumors. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Testicular adrenal rests'",
"    </a>",
"    below.) In addition to the ovary, adrenal rest tumors have been found in the",
"    <span class=\"nowrap\">",
"     paraovarian/adnexal",
"    </span>",
"    area. The tumors are difficult to identify by imaging, and most have been identified during surgery or at autopsy. Imaging with",
"    <span class=\"nowrap\">",
"     18FDG-PET/CT",
"    </span>",
"    localized rest tissue in three women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/72-74\">",
"     72-74",
"    </a>",
"    ] (including one with Nelson&rsquo;s syndrome); in one case, tumors were only visible after administration of cosyntropin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/73\">",
"     73",
"    </a>",
"    ]. The etiology appears related to sustained elevations in ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Male reproduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reproductive function may be impaired in men with 21-hydroxylase deficiency. Affected boys or young men may have no symptoms or signs of androgen excess. However, they may have testicular masses composed of adrenal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Testicular adrenal rests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular adrenal rest tumors, which are testicular masses composed of adrenal-like tissue, are common in male patients with 21-hydroxylase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation that these tumors resemble adrenal tissue comes from a study of eight adult patients who underwent testis-sparing surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/78\">",
"     78",
"    </a>",
"    ]. Adrenal-specific steroid secretion was documented with preoperative spermatic vein sampling, and expression of adrenal-specific enzymes and ACTH receptors was confirmed in tumor tissue.",
"   </p>",
"   <p>",
"    The clinical features of testicular rest tumors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are usually diagnosed between the ages of 10 and 20 years, but may be found as early as age five [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/79-81\">",
"       79-81",
"      </a>",
"      ]. In one report of 34 boys with classic 21-hydroxylase deficiency between the ages of 2 and 18 years who were undergoing testicular ultrasonography, eight (24 percent) were diagnosed with testicular adrenal rests; two of the boys were age seven [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/81\">",
"       81",
"      </a>",
"      ]. A similar prevalence was reported in a second report of 19 boys (mean age 5.6 years, range 2 to 10 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/82\">",
"       82",
"      </a>",
"      ]. Inhibin B and anti-m&uuml;llerian hormone concentrations were lower in patients compared with age-matched controls, suggesting that gonadal dysfunction was also present.",
"     </li>",
"     <li>",
"      Ultrasound studies suggest that the majority of adolescent and adult males with 21-hydroxylase deficiency have testicular adrenal rests (18 of 21 [86 percent] and 16 of 17 [94 percent] in two reports) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/76,77,83\">",
"       76,77,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They are more common in patients with the salt-losing form than the simple-virilizing form, as the former tend to have poorer control and higher ACTH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/84\">",
"       84",
"      </a>",
"      ]. However, a correlation between ACTH levels and tumor growth is not always seen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They are typically bilateral and vary in size from 2 to 40 mm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They may lead to obstruction of seminiferous tubules, gonadal dysfunction, and infertility (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Infertility'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Some, but not all, regress during glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. A minority of patients with large adrenal rest tumors eventually requires surgery for pain relief. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\", section on 'Testicular adrenal rests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the high prevalence of testicular adrenal rests and their association with infertility in male patients with 21-hydroxylase deficiency, we suggest screening testicular ultrasonography in adolescence or early adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with 21-hydroxylase deficiency are fertile as adults, but others have evidence of Leydig cell failure or impaired spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/76,77,87\">",
"     76,77,87",
"    </a>",
"    ]. As noted above, testicular adrenal rests may be associated with seminiferous tubule obstruction, gonadal dysfunction, and infertility. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Testicular adrenal rests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In one study of 17 adolescent and adult men, serum testosterone concentrations were low in six, and seven had abnormal semen analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/76\">",
"     76",
"    </a>",
"    ]. In a second report of 30 men, those with adrenal rests in the testes were more likely to be infertile [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Epinephrine deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenomedullary function is compromised in patients with classic congenital adrenal hyperplasia, as illustrated in a study of 38 children with classic 21-hydroxylase deficiency. Plasma epinephrine and metanephrine concentrations and urinary epinephrine excretion were 40 to 80 percent lower than in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/88\">",
"     88",
"    </a>",
"    ]. In three patients who underwent bilateral adrenalectomy, the adrenal medulla was poorly formed and the cells contained few vesicles.",
"   </p>",
"   <p>",
"    In a second study, the epinephrine response to exercise was significantly reduced in patients with classic 21-hydroxylase deficiency compared with healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/89\">",
"     89",
"    </a>",
"    ], and stress doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    did not improve the response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, 21-hydroxylase deficiency compromises both the development and subsequent functioning of the adrenomedullary system in severely affected cases. The combination of cortisol deficiency and epinephrine deficiency puts patients at risk for hypoglycemia with illness or prolonged fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/89\">",
"     89",
"    </a>",
"    ]. Adrenomedullary function has not been studied in patients with nonclassic congenital adrenal hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical findings that have been described include adrenal incidentalomas, pituitary adenomas, insulin resistance, and hyperleptinemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although 60 percent of patients with unilateral adrenal incidentalomas, and even more of those with bilateral incidentalomas, have exaggerated serum 17-hydroxyprogesterone responses to ACTH stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1\">",
"       1",
"      </a>",
"      ], the prevalence of germline",
"      <em>",
"       CYP21A2",
"      </em>",
"      mutations is low. However, unilateral and bilateral adrenal incidentalomas were found in 10 of 12 patients with simple virilizing and five of seven patients with late-onset CAH, as well as 9 of 10 heterozygotic siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/91\">",
"       91",
"      </a>",
"      ]. Most tumors had a diameter of less than 2 cm, but three patients had masses more than 5 cm in size. Adrenal masses in children with",
"      <em>",
"       CYP21A2",
"      </em>",
"      deficiency are usually benign [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pituitary microadenomas or empty sella may be found, but symptomatic corticotroph tumors have not been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/1,92\">",
"       1,92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insulin resistance has been reported in patients with both classic [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/93\">",
"       93",
"      </a>",
"      ] and nonclassic [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/94\">",
"       94",
"      </a>",
"      ] 21-hydroxylase deficiency. Hyperandrogenism, glucocorticoid therapy, and epinephrine deficiency have all been implicated as possible risk factors for insulin resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/14,93,94\">",
"       14,93,94",
"      </a>",
"      ]. Hyperleptinemia has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/93,95\">",
"       93,95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     P450 OXIDOREDUCTASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apparent combined 21-hydroxylase and 17-hydroxylase deficiency, a rare variant, has been described, but mutations in the",
"    <em>",
"     CYP21A2",
"    </em>",
"    and",
"    <em>",
"     CYP17",
"    </em>",
"    genes have not been identified in these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/96\">",
"     96",
"    </a>",
"    ]. Affected girls are born with ambiguous genitalia, suggesting intrauterine androgen excess; however, after birth, serum androgen concentrations are low, and virilization does not progress. Bone malformations affecting primarily the head and limbs (Antley-Bixler syndrome) are also sometimes present in boys and girls with this disorder.",
"   </p>",
"   <p>",
"    In two studies of six affected children and one woman, mutations were identified in the gene encoding P450 oxidoreductase (an enzyme that is important for transferring electrons to 21-hydroxylase and 17-hydroxylase) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/49/11034/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The finding of prenatal androgen excess and postnatal androgen deficiency in these patients suggests that there may be an alternative pathway in androgen synthesis present during fetal life.",
"   </p>",
"   <p>",
"    CYP17 deficiency is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=see_link\">",
"       \"Patient information: Congenital adrenal hyperplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 95 percent of cases of congenital adrenal hyperplasia are due to 21-hydroxylase due to",
"    <em>",
"     CYP21A2",
"    </em>",
"    mutations. It is one of the most common known autosomal recessive disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not always possible to predict the phenotype of these patients from the specific mutation(s) of the",
"      <em>",
"       CYP21A2",
"      </em>",
"      gene, but there are general correlations between genotype and phenotype.",
"     </li>",
"     <li>",
"      Classic 21-hydroxylase deficiency results in one of two clinical syndromes: a salt-losing form and the simple virilizing form. Girls with both forms present as neonates with ambiguous genitalia. Boys present as neonates with a salt-losing adrenal crisis (salt-losing form) (hyponatremia, hyperkalemia, and failure to thrive) or as toddlers with signs of puberty (simple virilizing form).",
"     </li>",
"     <li>",
"      Reproductive abnormalities are common in females and include structural abnormalities due to androgen excess in utero and anovulatory menstrual cycles.",
"     </li>",
"     <li>",
"      In adult men, testicular masses (adrenal rests), Leydig cell dysfunction, and abnormal semen analyses may be seen.",
"     </li>",
"     <li>",
"      Nonclassic or late-onset 21-hydroxylase deficiency may present as hirsutism and menstrual irregularity in young women, early pubarche or sexual precocity in school age children, or there may be no symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=see_link\">",
"       \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis and treatment of classic 21-hydroxylase deficiency are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=see_link\">",
"       \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"       \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/1\">",
"      White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/2\">",
"      Pang SY, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/3\">",
"      Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/4\">",
"      Pang, S, Clark, A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/5\">",
"      Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/6\">",
"      Lee HH, Kuo JM, Chao HT, et al. Carrier analysis and prenatal diagnosis of congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in Chinese. J Clin Endocrinol Metab 2000; 85:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/7\">",
"      New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin Endocrinol Metab 1995; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/8\">",
"      Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1995; 126:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/9\">",
"      Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/10\">",
"      Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/11\">",
"      Ferenczi A, Garami M, Kiss E, et al. Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/12\">",
"      Tiitinen A, V&auml;lim&auml;ki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002; 87:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/13\">",
"      Baumgartner-Parzer SM, Nowotny P, Heinze G, et al. Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005; 90:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/14\">",
"      Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/15\">",
"      Witchel SF, Lee PA, Suda-Hartman M, et al. Evidence for a heterozygote advantage in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997; 82:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/16\">",
"      Carroll MC, Campbell RD, Porter RR. Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci U S A 1985; 82:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/17\">",
"      White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci U S A 1985; 82:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/18\">",
"      White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 1986; 83:5111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/19\">",
"      Higashi Y, Yoshioka H, Yamane M, et al. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci U S A 1986; 83:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/20\">",
"      Miller WL. Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1994; 78:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/21\">",
"      L'Allemand D, Tardy V, Gr&uuml;ters A, et al. How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2000; 85:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/22\">",
"      Miller WL. Gene conversions, deletions, and polymorphisms in congenital adrenal hyperplasia. Am J Hum Genet 1988; 42:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/23\">",
"      Cooper DN, Ball EV, Krawczak M. The human gene mutation database. Nucleic Acids Res 1998; 26:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/24\">",
"      Laji�� S, Clauin S, Robins T, et al. Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab 2002; 87:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/25\">",
"      Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, et al. CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations. J Clin Endocrinol Metab 2003; 88:3852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/26\">",
"      Billerbeck AE, Mendonca BB, Pinto EM, et al. Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect. J Clin Endocrinol Metab 2002; 87:4314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/27\">",
"      Speiser PW, Dupont J, Zhu D, et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/28\">",
"      Wedell A, Thil&eacute;n A, Ritz&eacute;n EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994; 78:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/29\">",
"      Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995; 80:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/30\">",
"      J&auml;&auml;skel&auml;inen J, Levo A, Voutilainen R, Partanen J. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997; 82:3293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/31\">",
"      Ordo&ntilde;ez-S&aacute;nchez ML, Ram&iacute;rez-Jim&eacute;nez S, L&oacute;pez-Gutierrez AU, et al. Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of apparent germ-line mutations. Hum Genet 1998; 102:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/32\">",
"      Nimkarn S, Cerame BI, Wei JQ, et al. Congenital adrenal hyperplasia (21-hydroxylase deficiency) without demonstrable genetic mutations. J Clin Endocrinol Metab 1999; 84:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/33\">",
"      Koyama S, Toyoura T, Saisho S, et al. Genetic analysis of Japanese patients with 21-hydroxylase deficiency: identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J Clin Endocrinol Metab 2002; 87:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/34\">",
"      Finkielstain GP, Chen W, Mehta SP, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2011; 96:E161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/35\">",
"      Higashi Y, Hiromasa T, Tanae A, et al. Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 1991; 109:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/36\">",
"      Mornet E, Cr&eacute;t&eacute; P, Kuttenn F, et al. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet 1991; 48:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/37\">",
"      Owerbach D, Ballard AL, Draznin MB. Salt-wasting congenital adrenal hyperplasia: detection and characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using the polymerase chain reaction. J Clin Endocrinol Metab 1992; 74:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/38\">",
"      Dardis A, Bergada I, Bergada C, et al. Mutations of the steroid 21-hydroxylase gene in an Argentinian population of 36 patients with classical congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 1997; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/39\">",
"      Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 2000; 85:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/40\">",
"      Deneux C, Tardy V, Dib A, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2001; 86:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/41\">",
"      Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2003; 88:5680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/42\">",
"      Grigorescu Sido A, Weber MM, Grigorescu Sido P, et al. 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005; 90:5769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/43\">",
"      Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/44\">",
"      Charmandari E, Merke DP, Negro PJ, et al. Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and/or psychologic vulnerability to stress. J Clin Endocrinol Metab 2004; 89:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/45\">",
"      Joint LWPES/ESPE CAH Working Group.. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87:4048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/46\">",
"      Eugster EA, Dimeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001; 138:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/47\">",
"      Berenbaum, SA, Snyder, E. Early hormonal influences on childhood sex-typed activity and playmate preferences: implications for the development of sexual orientation. Dev Psychol 1995; 31:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/48\">",
"      Dittmann RW, Kappes MH, Kappes ME, et al. Congenital adrenal hyperplasia. I: Gender-related behavior and attitudes in female patients and sisters. Psychoneuroendocrinology 1990; 15:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/49\">",
"      Berenbaum SA. Effects of early androgens on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia. Horm Behav 1999; 35:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/50\">",
"      Zucker KJ, Bradley SJ, Oliver G, et al. Psychosexual development of women with congenital adrenal hyperplasia. Horm Behav 1996; 30:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/51\">",
"      Berenbaum SA, Resnick SM. Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia. Psychoneuroendocrinology 1997; 22:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/52\">",
"      Mathews GA, Fane BA, Conway GS, et al. Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure. Horm Behav 2009; 55:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/53\">",
"      Voutilainen R. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr 2000; 89:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/54\">",
"      Berenbaum SA, Korman Bryk K, Duck SC, Resnick SM. Psychological adjustment in children and adults with congenital adrenal hyperplasia. J Pediatr 2004; 144:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/55\">",
"      Berenbaum SA. Cognitive function in congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/56\">",
"      Johannsen TH, Ripa CP, Reinisch JM, et al. Impaired cognitive function in women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/57\">",
"      Nass R, Baker S. Androgen effects on cognition: congenital adrenal hyperplasia. Psychoneuroendocrinology 1991; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/58\">",
"      Helleday J, Bartfai A, Ritz&eacute;n EM, Forsman M. General intelligence and cognitive profile in women with congenital adrenal hyperplasia (CAH). Psychoneuroendocrinology 1994; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/59\">",
"      Kelso WM, Nicholls ME, Warne GL, Zacharin M. Cerebral lateralization and cognitive functioning in patients with congenital adrenal hyperplasia. Neuropsychology 2000; 14:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/60\">",
"      Malouf MA, Migeon CJ, Carson KA, et al. Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2006; 65:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/61\">",
"      Mueller SC, Temple V, Oh E, et al. Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH). Psychoneuroendocrinology 2008; 33:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/62\">",
"      Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/63\">",
"      Meyer-Bahlburg HF. What causes low rates of child-bearing in congenital adrenal hyperplasia? J Clin Endocrinol Metab 1999; 84:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/64\">",
"      Klingensmith GJ, Garcia SC, Jones HW, et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977; 90:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/65\">",
"      Richards GE, Grumbach MM, Kaplan SL, Conte FA. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 47:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/66\">",
"      Stikkelbroeck NM, Hermus AR, Braat DD, Otten BJ. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Obstet Gynecol Surv 2003; 58:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/67\">",
"      Urban MD, Lee PA, Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978; 299:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/68\">",
"      Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/69\">",
"      Nordenskj&ouml;ld A, Holmdahl G, Fris&eacute;n L, et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008; 93:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/70\">",
"      Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999; 84:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/71\">",
"      Stikkelbroeck NM, Hermus AR, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004; 14:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/72\">",
"      Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Horm Res Paediatr 2010; 74:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/73\">",
"      Crocker MK, Barak S, Millo CM, et al. Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97:E2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/74\">",
"      Lila AR, Malhotra G, Sarathi V, et al. Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism. J Clin Endocrinol Metab 2010; 95:5172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/75\">",
"      Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/76\">",
"      Stikkelbroeck NM, Otten BJ, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:5721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/77\">",
"      Stikkelbroeck NM, Suliman HM, Otten BJ, et al. Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. Eur Radiol 2003; 13:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/78\">",
"      Claahsen-van der Grinten HL, Otten BJ, Sweep FC, et al. Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. J Clin Endocrinol Metab 2007; 92:3674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/79\">",
"      Vanzulli A, DelMaschio A, Paesano P, et al. Testicular masses in association with adrenogenital syndrome: US findings. Radiology 1992; 183:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/80\">",
"      Avila NA, Shawker TS, Jones JV, et al. Testicular adrenal rest tissue in congenital adrenal hyperplasia: serial sonographic and clinical findings. AJR Am J Roentgenol 1999; 172:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/81\">",
"      Claahsen-van der Grinten HL, Sweep FC, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007; 157:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/82\">",
"      Martinez-Aguayo A, Rocha A, Rojas N, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92:4583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/83\">",
"      Falhammar H, Nystr&ouml;m HF, Ekstr&ouml;m U, et al. Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. Eur J Endocrinol 2012; 166:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/84\">",
"      Stikkelbroeck NM, Hermus AR, Suliman HM, et al. Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. J Pediatr Endocrinol Metab 2004; 17:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/85\">",
"      Rutgers JL, Young RH, Scully RE. The testicular \"tumor\" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988; 12:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/86\">",
"      J&oacute;dar-Gimeno, E, Fern&aacute;ndez-Soto, ML, Escobar-Jimenez, F, et al. Association between congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency and bilateral testicular tumors: a report of two cases. Endocrinologist 1997; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/87\">",
"      Newfield RS, New MI. 21-hydroxylase deficiency. Ann N Y Acad Sci 1997; 816:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/88\">",
"      Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000; 343:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/89\">",
"      Weise M, Mehlinger SL, Drinkard B, et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high-intensity exercise. J Clin Endocrinol Metab 2004; 89:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/90\">",
"      Weise M, Drinkard B, Mehlinger SL, et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab 2004; 89:3679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/91\">",
"      Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 74:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/92\">",
"      Charmandari E, Chrousos GP, Merke DP. Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2005; 18:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/93\">",
"      Charmandari E, Weise M, Bornstein SR, et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 2002; 87:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/94\">",
"      Speiser PW, Serrat J, New MI, Gertner JM. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/95\">",
"      Riepe FG, Krone N, Kr&uuml;ger SN, et al. Absence of exercise-induced leptin suppression associated with insufficient epinephrine reserve in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Exp Clin Endocrinol Diabetes 2006; 114:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/96\">",
"      Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/49/11034/abstract/97\">",
"      Fl&uuml;ck CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 149 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11034=[""].join("\n");
var outline_f10_49_11034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genotype versus phenotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infants/children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sexual behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Female reproduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Male reproduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Testicular adrenal rests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Epinephrine deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      P450 OXIDOREDUCTASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/149|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1278\" title=\"figure 1\">",
"      21 hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/149|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/52/19266\" title=\"picture 1\">",
"      Clitoromegaly1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19560?source=related_link\">",
"      Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/56/19330?source=related_link\">",
"      Patient information: Congenital adrenal hyperplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7433?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_49_11035="Calculation maintenance fluid";
var content_f10_49_11035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calculation of maintenance fluids based on body weight (Wt) in children and infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Body Wt",
"        <br/>",
"        (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily maintenance fluid*",
"        <br/>",
"        (mL/24 hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hourly maintenance fluid*",
"        <br/>",
"        (mL/hour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-10",
"       </td>",
"       <td>",
"        100 x Wt (kg)",
"       </td>",
"       <td>",
"        4 x Wt (kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10-20",
"       </td>",
"       <td>",
"        1000 plus 50 x Wt over 10 kg",
"       </td>",
"       <td>",
"        40 plus 2 x Wt over 10 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        1500 plus 20 x Wt over 20 kg",
"       </td>",
"       <td>",
"        60 plus 1 x Wt over 20 kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maximum fluid per 24 hours is 2400 mL or 100 mL/hour.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11035=[""].join("\n");
var outline_f10_49_11035=null;
var title_f10_49_11036="Serious medical complications of stroke";
var content_f10_49_11036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serious medical complications of stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All pneumonias",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration pneumonia alone",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal bleeding",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac arrest",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angina/MI/cardiac ischemia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep venous thrombosis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellulitis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vascular disorder",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dehydration",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    In a prospective study that analyzed the placebo group of the RANTTAS database (n = 279), at least one serious medical complication (defined as prolonged, immediately life threatening, or resulting in hospitalization or death) occurred in 24 percent of patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Johnston, KC, Li, JY, Lyden, PD, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 1998; 29:447.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11036=[""].join("\n");
var outline_f10_49_11036=null;
var title_f10_49_11037="Penile ulcer dark field answer";
var content_f10_49_11037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treponema pallidum: darkfield microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dark field examination of exudate from a penile ulcer (x1000) in a patient with syphilis. The spirochete Treponema pallidum, which is too small to be seen using ordinary microscopy, appears as a delicate spiral rod when dark field illumination is employed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11037=[""].join("\n");
var outline_f10_49_11037=null;
var title_f10_49_11038="Contents: Hospital oncology";
var content_f10_49_11038=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital oncology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital oncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41178\">",
"           Approach to symptom assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30842\">",
"           Cancer pain management with opioids: Optimizing analgesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9290\">",
"           Cancer pain management with opioids: Prevention and management of side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39066\">",
"           Cancer pain management: Adjuvant analgesics (coanalgesics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43704\">",
"           Cancer pain management: General principles and risk management for patients receiving opioids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4488\">",
"           Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19338\">",
"           Malignancy-related superior vena cava syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43064\">",
"           Neurologic complications of cancer treatment with biologic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43530\">",
"           Neurologic complications of non-platinum cancer chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/23/37242\">",
"           Neurologic complications of platinum-based chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24201\">",
"           Preoperative management of patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39210\">",
"           Prevention and treatment of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29769\">",
"           Psychosocial issues at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29770\">",
"           The role of parenteral and enteral/oral nutritional support in patients with cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E7CCDA32E1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_49_11038=[""].join("\n");
var outline_f10_49_11038=null;
var title_f10_49_11039="S pneumoniae in CSF";
var content_f10_49_11039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    under high-power magnification (1000x) in CSF.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_49_11039=[""].join("\n");
var outline_f10_49_11039=null;
